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1. Introduction 
Many studies in the social and epidemiological sciences aim to make causal inferences using 
observational data. This is often problematic, as observed associations are not necessarily causal, with 
confounding being an important concern. Randomization of treatment, as in a Randomized Controlled 
Trial (RCT), is one way to infer causality. However, such experiments are not always possible or feasible. 
An approach commonly used in the economics and econometrics literature is that of Instrumental Variables 
(IV). This introduces a third variable (the instrument) that is robustly associated with the risk factor of 
interest, but not with the outcome variable, other than through its effect on the risk factor. This instrument 
can then be exploited to make causal inferences about the effect of the risk factor on the outcome. 
Recently, epidemiologists, statisticians, economists and other social scientists have become interested 
in using genetic variants as instruments. ‘Mendelian randomization’ refers to the random assignment of an 
individual’s genotype at conception (Davey Smith and Ebrahim, 2003; Davey Smith, 2007). Under certain 
assumptions that we discuss in detail below, observed associations between genetic variants and the 
outcome of interest are unlikely to be due to confounding by behavioural or environmental factors. 
Mendelian randomization can therefore be exploited to make causal inferences about the effects of 
modifiable (non-genetic) risk factors, on different outcomes.1 Statisticians have highlighted some of the 
implicit statistical assumptions commonly made in Mendelian randomization studies (e.g. Didelez and 
Sheehan, 2007; Didelez et al., 2010). Genetic epidemiologists emphasize the importance of carefully 
examining the conditions that need to be met for genetic variants to be used as instruments (see e.g. Davey 
Smith and Ebrahim, 2003; Sheehan et al. 2008; Lawlor et al., 2008). However, while studies in economics 
commonly use IV methods, the (biological) conditions relevant for Mendelian randomization have not been 
disseminated widely in this literature. The increasing availability of biomedical information in social science 
datasets, however, makes understanding them crucial to the successful use of genotypes as instruments for 
modifiable risk factors.  
The contribution of this paper is to discuss these conditions within the well-known statistical potential 
outcomes framework. We use the work by Imbens and Angrist (1994), Angrist, Imbens and Rubin (1996), 
and Angrist, Graddy and Imbens (2000), among others, which has been of great importance in linking the 
econometric IV literature to the potential outcomes framework. We link Mendelian randomization to this 
framework, and discuss how the conditions, defined in genetic epidemiology, relate to the IV assumptions 
used in statistics and economics. To communicate best practice in genetic epidemiology to a wider 
economics audience, we review these conditions in the context of two illustrative applications: one in social 
science and one in medicine. Specifically, we examine whether child fat mass causally affects (1) academic 
achievement, and (2) blood pressure, using 32 recently identified genetic variants as instrumental variables 
for fat mass.   
These examples are pertinent for several reasons. For our social science application for example, obese 
children are more likely to be absent from school, have sleep disorders, and be treated differently by 
                                                 
1 Appendix A provides a brief guide to the terms used in genetic studies. 
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teachers, parents and peers. All these may affect children’s (learning) environment and educational 
outcomes. However, an observed association between fat mass and academic achievement is not necessarily 
causal. There are likely to be many confounders, and one can never be sure that all relevant ones are 
accounted for. For our medical application, there is evidence that even relatively small reductions in weight 
can reduce blood pressure and hypertension risk (Neter et al., 2003). However, the increase in obesity in 
recent decades has been accompanied by a decrease in hypertension, leading to questions about their 
association, with some suggesting that randomized controlled trials of weight reduction could have affected 
blood pressure through mechanisms other than weight loss (Campos et al., 2006). The use of ordinary least 
squares (OLS) suggests that fat mass is inversely related to educational attainment, but increases the risk of 
hypertension. When using carefully selected genetic variants as instruments for fat mass, we find no 
evidence of a causal relationship between fat mass and academic performance, although the parameters are 
imprecisely estimated. In contrast, we find a positive effect of fat mass on blood pressure, suggesting that 
reductions in fat mass will reduce the risk of cardiovascular disease.  
Although Mendelian randomization is widely used in the medical and epidemiological sciences, with its 
findings being fed into pharmacotherapeutic development, it is very controversial within economics. This 
mainly stems from the credibility of the ‘exclusion restriction’: the assumption that the variants do not 
directly affect the outcome of interest. Indeed, there are many situations that may violate this assumption, 
invalidating the instruments and biasing the estimates. One of the issues is that we have very limited 
knowledge and understanding of the specific functions of genes, and studies that directly examine gene-
function are often underpowered. Hence, we can never be certain that the exclusion restriction is satisfied. 
We discuss this in detail, and highlight the specific (biological) pathways through which the use of genetic 
variants as instrumental variables may lead to invalid inferences, including the potential for variants to have 
multiple functions, or to be correlated to other variants that affect the outcome of interest. We also consider 
the implications of gene-gene and gene-environment interactions for Mendelian randomization. Finally, it 
is worth noting that the uncertainty of the exclusion restriction is not specific to Mendelian randomization. 
Indeed, any IV analysis relies on this untestable assumption, and one generally assesses such studies based 
on whether the available evidence suggests that the assumption is likely to hold. We discuss different ways 
of exploring its validity indirectly in the context of Mendelian randomization and attempt to clearly 
articulate the potential situations that would invalidate the approach.2  
Section 2 details the conditions that need to be met for genetic variants to be used as instruments. 
Section 3 introduces our empirical application. We describe the data, examine the validity of our choice of 
genetic variants, present the results as well as a number of sensitivity checks. Section 4 concludes and 
discusses the implications of our findings in terms of best practice for using Mendelian randomization by 
researchers who do not come from a primarily biological discipline.  
 
                                                 
2 Thus we give below examples of situations where the use of genetic variants as instrumental variables is more as well 
as less likely to lead to incorrect inference. 
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2. The Use of Genetic Variants as Instrumental Variables 
We start by discussing the links between Mendelian randomization and other approaches used in the 
medical and social science literature. We then build on the Potential Outcomes Framework by Imbens and 
Angrist (1994), Angrist and Imbens (1995), Angrist, Imbens and Rubin (1996), and Angrist, Graddy and 
Imbens (2000). We first briefly outline the well-known structural assumptions in the context of our 
applications, and then discuss how Mendelian randomization links to the statistical assumptions of this 
framework. 
 
2.1 Mendelian Randomization 
We discuss Mendelian randomization from a statistics and economics perspective in the context of a 
social study, with the aim of making causal inferences about the effect of a treatment on an outcome of 
interest. Depending on the discipline, the terms ‘treatment’, ‘risk factor’, ‘exposure’, ‘predictor’, or 
‘intermediate phenotype’ have all been used to denote the variable of interest that potentially causes the 
outcome. To avoid confusion, the remainder of this paper uses either the term ‘treatment’ or ‘risk factor’. 
The concept of Mendelian randomization is closely linked to Randomised Controlled Trials (RCTs), 
where the allocation of treatment is randomised over all eligible individuals (Davey Smith and Ebrahim, 
2005; Hingorani and Humphries, 2005). Indeed, IV can be applied to analyse encouragement designs (such 
as RCTs where the instrument is the encouragement to participate) that are affected by non-ignorable non-
compliance. Non-compliance refers to the fact that individuals can choose to take or not take treatments 
other than those to which they are randomised. Non-ignorable non-compliance refers to participants 
choosing to take or not to take the treatment that they are randomised to in a manner associated with their 
study outcomes, after adjusting for baseline characteristics. This is also known as endogenous treatment in 
economics, or selection into treatment. 
The idea is similar for the social context in our application: individuals ‘select’ their treatment – fat mass 
– through lifestyle choices, such as diet and physical activity, which are likely to be related to their study 
outcome (educational attainment and blood pressure). In a well-conducted RCT of an intervention aimed 
at reducing fat mass, the random allocation effectively balances these lifestyle choices between groups. 
Comparing groups based on the original random allocation (‘intention to treat’) maintains this balance, 
whereas comparing groups based on what treatment was actually chosen by the participant (a ‘per-protocol’ 
analysis) is likely to be biased due to non-ignorable non-compliance. In other words, treatment by choice 
(as opposed to treatment by randomisation) is likely to be related to the outcome through characteristics 
such as social class, income, diet, etc.  
There are many cases, however, where RCTs are infeasible (for example, there may be no effective 
intervention to randomize, such as for adiposity) or unethical (for example, when examining the effect of 
prenatal alcohol consumption on different outcomes). In such cases, quasi-experimental designs such as 
Mendelian randomization experiments can provide a useful alternative approach. 
As in RCTs, Mendelian randomization assumes that characteristics such as social class, income and diet 
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are balanced across the genotypes. This assumption exploits the fact that there is an equal probability that 
either parental allele (see Appendix A) is transmitted to offspring. As this allocation is random at the family 
trio level, the cleanest experiment is one with biological siblings, examining randomization of genes within 
families (Davey Smith and Ebrahim, 2003). However, also at a population level, many studies suggest that 
genetic variants are largely unrelated to the many socioeconomic and behavioural characteristics that are 
closely linked with each other and that confound conventional observational studies (Bhatti et al., 2005; 
Davey Smith et al., 2008; Kivimäki et al., 2008; Lawlor et al., 2008; von Hinke et al., 2013; see also Fisher, 
1952 and Box 2010). Hence, as genes are randomly assigned during meiosis (cell division for reproduction), 
individuals of different genotypes are expected not to differ systematically in any other respect. The issue 
of compliance in Mendelian randomization studies is discussed further in Section 2.2. 
Interventional studies such as RCTs, where treatment is introduced at a certain age, identify the effect 
of differences in treatment from that point in time. By contrast, estimates from Mendelian randomization 
experiments exploit differences in treatment throughout life, estimating the long term (cumulative) effects 
of the treatment on the outcome of interest (Davey Smith and Ebrahim, 2005).  
As noted by Didelez and Sheehan (2007), the potential limitations of Mendelian randomization studies 
fall into two sets. First, limitations related to the implicit statistical assumptions common in many Mendelian 
randomization studies, such as linearity and additivity. As these have been discussed in detail (e.g. Didelez 
and Sheehan, 2007; Didelez et al., 2010), we focus on the second set of limitations: those relating to the 
assumptions of the validity of the instrument. Genetic epidemiology studies emphasize the importance of 
carefully examining several situations and (biological) processes that may violate the IV assumptions (see 
e.g. Davey Smith and Ebrahim, 2003; Sheehan et al. 2008; Lawlor et al., 2008). The increasing availability 
of biomedical information in social science datasets makes understanding of these conditions crucial to the 
successful use of genotypes as instruments for modifiable risk factors. We therefore first outline the 
structural assumptions in the context of our applications, discuss the concepts defined in epidemiology and 
relate them to the assumptions that need to be met to obtain causal estimates of the effect of the risk factor 
on the outcome of interest, as defined in the statistics and economics literature.  
 
2.2 The Potential Outcomes Framework 
Our two illustrative applications use a continuous treatment and outcome variable, and 32 independent 
genetic variants. For ease of exposition, however, we discuss our framework for the case of two genetic 
variants, though we note that this is easily generalised to incorporate any number of variants. As shown in 
Angrist, Graddy and Imbens (2000), with such discrete instruments, the number of instruments is irrelevant; 
it is the number of distinct values of the instrument vector that matters. Hence, with two genetic variants 
(denoted by 𝑍1 and 𝑍2), we observe nine instrumental values, defined by the combination of the number 
of rare alleles. Without loss of generality, we order the instruments by their mean fat mass, for example: 
(𝑍1, 𝑍2) ∈ {(0,0), (0,1), (1,0), (0,2)(1,1), (1,2), (2,0), (2,1), (2,2)}. We can represent this as an 
instrument 𝑍 with support 1,2,…,9; the full set of instruments are the nine mutually exclusive dummy 
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variables. Let 𝐴 and 𝑌 denote random variables representing, respectively, fat mass and the educational 
outcome / blood pressure.  
Let 𝐴𝑖(𝑧) be the potential fat mass for individual 𝑖 when the instrument is set to 𝑧. Only one of the 9 
possible treatment assignments 𝐴𝑖(1), 𝐴𝑖(2), …, 𝐴𝑖(9) is ever observed for any one individual. Similarly, 
let 𝑌𝑖(𝑧, 𝑎) be the potential outcome for individual 𝑖 that would be obtained if 𝑖‘s fat mass, the treatment 
variable, was set to 𝑎 and the instrument was set to 𝑧. We refer to 𝐴𝑖(𝑧) and 𝑌𝑖(𝑧, 𝑎) as the potential 
treatments and potential outcomes respectively. Similar to 𝐴𝑖(𝑧), only one of the 9 potential outcomes 
𝑌𝑖(1, 𝐴𝑖(1)), 𝑌𝑖(2, 𝐴𝑖(2)), …, 𝑌𝑖(9, 𝐴𝑖(9)) can ever be observed for any one individual.  
We follow convention and assume that individual 𝑖’s potential treatments and potential outcomes are 
independent of the outcome and treatment status of other individuals. This is also referred to as the Stable 
Unit Treatment Value Assumption (SUTVA, see e.g. Rubin, 1980).  
Given the set of potential outcomes, we can define the causal effects for individual 𝑖 of 𝑍 on 𝐴 as 
(𝐴𝑖(𝑧) − 𝐴𝑖(𝑧 − 1)), and the causal effects for individual 𝑖 of 𝑍 on 𝑌 as (𝑌𝑖(𝑧, 𝐴𝑖(𝑧)) −
𝑌𝑖(𝑧 − 1, 𝐴𝑖(𝑧 − 1))), for 𝑧 ∈ {2, … ,9}. These are also known as the intention-to-treat effects.  
 
Assumption 1: Independence 
𝑍𝑖 ⫫ {𝑌𝑖(𝑧, 𝑎), 𝐴𝑖(𝑧)}𝑧,𝑎  
 
The independence assumption implies that the instrument is independent of all potential outcomes and 
potential treatments, for all values of 𝑧 and 𝑎. In other words, the instrument is as good as randomly 
assigned. Note that, as Mendelian randomization is closely related to RCTs, where the allocation of 
treatment is randomised over all eligible individuals, we specify the unconditional independence assumption. 
If the instruments are not independent of covariates, however, we require the conditional independence 
assumption, implying that independence holds conditional on some vector of covariates, defined by 𝐗.  We 
discuss the role of covariates in Mendelian randomization studies in more detail in Section 2.4.  
Given SUTVA and independence, we can obtain unbiased estimators for the average intention-to-treat 
effects by taking the difference of sample averages of the outcomes and treatments at different values of 
the instrument. 
 
Assumption 2: Exclusion 
𝑌𝑖(𝑧, 𝑎) = 𝑌𝑖(𝑧′, 𝑎),        for all 𝑧, 𝑧
′ and for all 𝑎. 
 
This implies that 𝑌𝑖(1, 𝑎) = 𝑌𝑖(2, 𝑎) =  …  = 𝑌𝑖(9, 𝑎), for all 𝑎, or that the potential outcomes, at any 
level of fat mass 𝑎, are unchanged by the value of the instrument. In other words, the only way through 
which the instrument affects the potential outcome is via 𝐴. It implies that 𝑌𝑖(𝑧, 𝑎) is a function of 𝑎 only, 
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and hence we can write 𝑌𝑖(𝑧, 𝑎) = 𝑌𝑖(𝑎). If the exclusion restriction only holds conditional on 𝐗, we can 
specify the exclusion restriction conditional on these covariates. 
With heterogeneous responses, the potential outcomes for individual 𝑖 can be written as a general 
function of 𝑎, say 𝑌𝑖(𝑎) ≡ 𝑔𝑖(𝑎). We can define the individual causal effects of 𝐴 on 𝑌 as the derivatives 
of 𝑔𝑖(𝑎). So the individual causal response is the difference in potential outcomes at each value of 𝑎.  
Although we can never observe any of these individual causal effects, we can observe the average causal 
effects for groups of individuals who can be induced to change treatment: 𝐸[𝑔𝑖
′(𝑞)|𝐴𝑖(𝑧) < 𝑞 < 𝐴𝑖(𝑧′)], 
where 𝑔𝑖
′(𝑞) is the derivative of 𝑔𝑖(𝑎) w.r.t. 𝑎 evaluated at 𝑞. Inferences about such average causal effects 
are made using changes in treatment status that are induced by the instrument (Angrist, Imbens and Rubin, 
1996). For this, we require the instrument to affect treatment status. 
 
Assumption 3: Non-zero effect of the instrument on treatment 
𝐸[𝐴𝑖(𝑧) − 𝐴𝑖(𝑧′)] ≠ 0, for all 𝑧, 𝑧′ 
 
This implies that expected potential fat mass is affected by the instrument and therefore that the 
instrument has an effect on the treatment. 
 
Assumption 4: Monotonicity 
𝑃[𝐴𝑖(𝑧) ≥ 𝐴𝑖(𝑧
′)] = 1       for all 𝑧 ≥ 𝑧′ or 
𝑃[𝐴𝑖(𝑧) ≤ 𝐴𝑖(𝑧′)] = 1,       for all 𝑧 ≤ 𝑧
′, 
 
for all 𝑖. This implies that the potential fat mass for individual 𝑖 with instrument value 𝑧 is at least as 
high as the potential fat mass for the same individual with instrument value 𝑧′, or vice versa, that the 
potential fat mass for individual 𝑖 with instrument value 𝑧 is lower than or equal to the potential fat mass 
for the same individual with instrument value 𝑧′, for all 𝑖.  
We use the above assumptions to interpret differences in average outcomes and treatments at different 
values of the instrument. Under these assumptions, the IV estimand is equal to a weighted average of the 
8 linearly independent average causal responses (ACRs), defined here as 𝜏𝑧,𝑧−1:  
 
𝜏𝑧,𝑧−1 =
𝐸[𝑌𝑖|𝑍𝑖 = 𝑧] − 𝐸[𝑌𝑖|𝑍𝑖 = 𝑧 − 1]
𝐸[𝐴𝑖|𝑍𝑖 = 𝑧] − 𝐸[𝐴𝑖|𝑍𝑖 = 𝑧 − 1]
 
=
∫ 𝐸[𝑔𝑖
′(𝑞)|𝐴𝑖(𝑧 − 1) < 𝑞 < 𝐴𝑖(𝑧)] 𝑃{𝐴𝑖(𝑧 − 1) < 𝑞 < 𝐴𝑖(𝑧)}𝑑𝑞
∫ 𝑃{𝐴𝑖(𝑧 − 1) < 𝑞 < 𝐴𝑖(𝑧)}𝑑𝑞
, for 𝑧 = 2, … ,9. 
 
In other words, each instrumental variable identifies a unique causal parameter, one specific to the 
subpopulation whose treatment is affected by the instrument. Different valid instruments may therefore 
lead to different causal parameters. Hence, IV estimation that uses each of the instruments one by one 
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weights the derivative function 𝑔𝑖
′(𝑞) by the strength of the instrument (Angrist, Graddy and Imbens, 2000; 
Angrist and Pischke, 2009). Let the points of support of 𝑍 be ordered such that 𝑙 < 𝑚 implies that 
𝐸[𝐴𝑖|𝑍𝑖 = 𝑙] < 𝐸[𝐴𝑖|𝑍𝑖 = 𝑚]. The IV estimand using all 9 mutually exclusive instruments can then be 
written as: 
                                  ∑ 𝜔𝑧𝜏𝑧,𝑧−1
9
𝑧=2 ,       (1) 
where 
𝜔𝑧 = (𝐸[𝐴𝑖|𝑍𝑖 = 𝑧] − 𝐸[𝐴𝑖|𝑍𝑖 = 𝑧 − 1]) ∙
∑ 𝜋𝑙(𝐸[𝐴𝑖|𝑍𝑖 = 𝑙] − 𝐸[𝐴𝑖])
9
𝑙=𝑧
∑ 𝜋𝑙𝐸[𝐴𝑖|𝑍𝑖 = 𝑙](𝐸[𝐴𝑖|𝑍𝑖 = 𝑙] − 𝐸[𝐴𝑖])
9
𝑙=1
 
 
and 𝜋𝑙 = 𝑃𝑟[𝑍 = 𝑙], 𝜔𝑧 > 0 and ∑ 𝜔𝑧𝑧 = 1.. Hence, it averages the (pairwise) instrument-specific 
weighted averages of the derivative function, where the weights are proportional to the instrument-induced 
change in the cumulative distribution function (CDF) of fat mass (Angrist and Imbens, 1995; Angrist, 
Graddy and Imbens, 2000; Angrist and Pischke, 2009). In other words, it combines a set of weighted 
average effects into a new weighted average.  
The above example is for a case with two genetic variants, or nine instrumental variables, which is 
straightforward to estimate in standard software packages. As discussed earlier, however, we observe 32 
genetic variants, and with that, a maximum of 332 instrumental variables.3 Instead of specifying a model 
with that many instruments, we use one ‘allelic score’, mapping the instrumental variables 𝑧 = 1, … , 332 
onto a function ℎ(𝑍𝑖), defined as the number of risk alleles carried by each child. In other words, for every 
individual, we sum the number of adiposity-increasing alleles for the 32 variants. For example, the allelic 
score for the above case of 9 instruments takes five values: 
(𝑍1, 𝑍2) ℎ(𝑍𝑖) 
(0,0) 0 
(0,1), (1,0) 1 
(1,1), (0,2), (2,0) 2 
(1,2), (2,1) 3 
(2,2) 4 
 
(in our sample, the allelic score using the 32 genetic variants takes one of 28 distinct values, see also Section 
3.4). Using the allelic score ℎ(𝑍𝑖), the IV estimand can be written as:  
𝐶𝑜𝑣(𝑌𝑖 , ℎ(𝑍𝑖))
𝐶𝑜𝑣(𝐴𝑖 , ℎ(𝑍𝑖))
. 
                                                 
3 Note that not all combinations of rare alleles may be observed in the data, reducing the total number of instruments. 
In addition, when multiple pairs of risk alleles give the same predicted treatment, one may condense the number of 
instrument values, leading to a further reduction in the total number of instruments (see Clarke, Palmer and 
Windmeijer, 2015). 
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Similar to (1), the IV estimand that uses the multivalued allelic score ℎ(𝑍𝑖) is a weighted average of the 
ACRs 𝜏𝑧,𝑧−1. However, the weights are now given by:  
 
𝜔𝑧 =
(𝐸[𝐴𝑖|𝑍𝑖 = 𝑧] − 𝐸[𝐴𝑖|𝑍𝑖 = 𝑧 − 1]) ∙ ∑ 𝜋𝑙
9
𝑙=𝑧 (ℎ(𝑍𝑖 = 𝑙) − 𝐸[ℎ(𝑍𝑖)])
∑ (𝐸[𝐴𝑖|𝑍𝑖 = 𝑚] − 𝐸[𝐴𝑖|𝑍𝑖 = 𝑚 − 1]) ∙ ∑ 𝜋𝑙
9
𝑙=𝑚 (ℎ(𝑍𝑖 = 𝑙) − 𝐸[ℎ(𝑍𝑖)])
9
𝑚=1
, 
 
where, again, 𝜋𝑙 = 𝑃𝑟[𝑍 = 𝑙], 𝜔𝑧 > 0 and ∑ 𝜔𝑧𝑧 = 1. As above, the weights are proportional to the first 
stage impact on the treatment (Angrist, Graddy and Imbens, 2000; Imbens and Wooldridge, 2009). Thus, 
inferences about the ACRs are made using changes in treatment status that are induced by the instrument. 
At this point, it may be useful to consider a situation where the instrument and treatment are binary, in 
which case we can stratify individuals into four latent groups, as commonly used in the econometrics 
literature (e.g. Angrist, Imbens and Rubin, 1996): those who are induced to take treatment by the instrument 
(compliers), those who do the opposite of their assignment (defiers), those who never take treatment, whatever 
their assignment (never-takers), and those who always take treatment, regardless of their assignment (always-
takers). In this framework, the IV estimate can be interpreted as a Local Average Treatment Effect (LATE) 
or Complier Average Causal Effect (CACE): the effect of treatment for those who are induced to take 
treatment by the instrument (the compliers). Indeed, LATE or CACE is not informative about effects on 
never- and always-takers, because (by definition) treatment status for these groups is not affected by the 
instrument. By virtue of the exclusion restriction, the causal effect of 𝑍 on 𝑌 for never-takers and always-
takers is zero. And by virtue of the monotonicity assumption, there are no defiers. Note that in the case of 
a continuous intermediate variable as generally used in Mendelian randomization studies (such as fat mass, 
lipids, energy intake, units of alcohol, number of cigarettes, etc.), it is unclear what it means to be a complier, 
defier, always-taker, or never-taker. A detailed discussion on identifying compliers in such cases is beyond 
the scope of this paper, but for different approaches, we refer the reader to Frangakis and Rubin (2002), 
Sjölander et al. (2009), Jin and Rubin (2008), and Bartolucci and Grilli (2011).  
 
2.3 Conditions for the Use of Genetic Variants as Instrumental Variables 
For a valid causal interpretation of the IV estimand that uses the genetic variants as instruments, we 
require the above assumptions to hold. However, there are various situations that may violate them, which 
need to be examined. We discuss these below. 
 
Assumption 1: Independence 
Although genotypes are randomly allocated at conception, the allele distribution may differ for 
different population subgroups. If these subgroups also have systematically different outcomes of interest, 
this could lead to an association between the two at the population level without an actual causal 
relationship. A systematic relationship between the allele frequency and the outcome of interest across 
different sub-populations is also referred to as ‘population stratification’. For example, allele frequencies 
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can vary across ethnic groups. Any systematic differences in the outcome of interest across these 
subpopulations that are not due to the genetic make-up may therefore lead to biased estimates of the effect 
of treatment by violating the independence Assumption 1. In other words, despite the fact that genotypes 
are randomly allocated and with that satisfy independence, any population stratification can violate this 
assumption. This can be dealt with, however, by examining the question of interest within ethnic groups, 
separately analyzing the different subpopulations, and/or adjusting for principal components from genome 
wide data that function as ancestry markers. These approaches then rely on the conditional independence 
assumption, assuming independence conditional on ethnicity or ancestry.  
As genotypes are randomly assigned given the parental genes, the presence of assortative mating based 
on genes can violate independence. The cleanest experiment, therefore, is one with biological siblings, 
examining randomization of genes within families (Davey Smith and Ebrahim, 2003). However, even when 
we only observe one individual per family, Mendelian randomization is valid if we are able to assume that, 
at the population level, genetic variants are unrelated to other characteristics that may affect the outcome 
of interest, as shown in many studies (Bhatti et al., 2005; Davey Smith et al., 2008; Kivimäki et al., 2008; 
Lawlor et al., 2008; von Hinke et al., 2013; see also Fisher, 1952). One way to indirectly test independence 
is by exploring whether the distribution of observable characteristics is the same in different groups defined 
by the value of the instrument (i.e. different genotypes). Indeed, if the instrument is randomized, there 
should be no systematic variation in the covariates by genotype, whether we use a within- or between-family 
analysis. This raises the question however, about which covariates to test for, as any characteristic is, in 
principle, a post-treatment variable with respect to the instrument. Hence, any systematic variation in these 
indirect tests does not necessarily indicate a violation of independence (see also Rubin, 2005). It may be, 
for example, that the instrument is picking up other causal effects of the same treatment. 
 
Assumption 2: Exclusion  
One can never directly test whether exclusion holds, and there are various situations in which 
Assumption 2 fails, invalidating the instruments. One such situation is that ‘behaviours’ may be affected by 
the genotype. As individuals inherit their genes from their parents, it may be important to consider whether 
parents’ behaviours or preferences are affected by their genotype (and hence their offspring’s genotype). 
This can bias studies that examine maternal behaviours that influence the outcome of interest via 
intrauterine effects. Likewise, it may be a problem in studies where parental behaviours influence the 
outcome via affecting their (child’s) behaviour.  
As an example of the former, if one were interested in the effect of an individual’s alcohol consumption 
on their later life liver disease using a genetic variant that robustly relates to alcohol intake, any intrauterine 
effects of maternal alcohol consumption during pregnancy on offspring liver development could violate 
Assumption 2. This is because the mother’s genotype is related to the offspring’s genotype (the instrument), 
and will influence her alcohol consumption throughout life, including potentially when she was pregnant. 
If maternal alcohol intake during pregnancy affects her offspring’s liver development in utero and its 
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functioning later in the child’s life, there is a link from the offspring’s genotype (IV) to the outcome (the 
offspring’s liver disease) via maternal genotype and maternal alcohol consumption, violating Assumption 
2.  
As an example of the latter, if one is interested in the effect of fat mass on education, as we are below, 
parents who carry ‘fat’ alleles may be discriminated against in the labour market because of their on average 
higher weights (Cawley, 2004). If this affects their behaviour or preferences for their child’s weight or 
education, Assumption 2 may be violated.  
A second situation relates to the mechanisms through which genetic variants affect the modifiable risk 
factor. These are often unknown. If the mechanism involves changes in behaviour or preferences that in 
addition to affecting the risk factor also directly affect the outcome, Assumption 2 will be violated. For 
example, if the fat related genetic variants that we use below influence fat mass because they are related to 
pathways associated with addiction more generally, such as addiction to high energy foods, and if the latter 
affects the outcome of interest, Assumption 2 would be violated. If the mechanism only results in changes 
to the risk factor but does not directly affect the outcome, the exclusion restriction is not violated.  
Thirdly, the genetic instrument may be related to other genetic variants that affect the outcome of 
interest. Mendel’s second law states that the inheritance of one trait is independent of the inheritance of 
another. However, it has been shown that this does not always hold and that some variants are likely to be 
co-inherited. This so-called ‘Linkage Disequilibrium’ (LD) does not occur for genetic variants on different 
(non-homologous) chromosomes, and the degree of LD is partly a function of the distance between the 
loci (see Appendix A for some of the genetic terms used here). Depending on the effects of the co-inherited 
variant, LD can bias the estimates. If our instrument is in LD with another polymorphic locus that affects 
only the modifiable risk factor, the IV estimates remain consistent. However, if it is in LD with a 
polymorphic locus that directly affects the outcome, Assumption 2 is violated. Relatedly, there is the 
situation of ‘pleiotropy’, where one genetic variant has multiple functions. The case is similar to that of LD, 
and will invalidate the IV approach if the pleiotropic effect influences the outcome directly, but not if it 
affects only other characteristics that are unrelated to the outcome of interest.  
Fourth, a biological process that may bias causal estimates in Mendelian randomization studies is 
‘canalisation’. This refers to the reduced sensitivity of a phenotype to the changes in underlying genetic and 
non-genetic factors that determine its expression. Hence, a canalised genotype produces the same (or a 
similar) phenotype in different genetic and non-genetic backgrounds (Flatt, 2005). For example, an 
individual who has a genetic variant associated with higher blood pressure may not experience adverse 
phenotypic effects of high blood pressure due to the arteries becoming resistant. This is difficult to test for, 
as the genetic variant may still be related to blood pressure, but any adverse health outcomes (phenotypes) 
normally caused by higher blood pressure would not occur. Hence, canalisation implies that the genotype 
can affect the outcome through alternative channels, altering the association between genotype and 
outcome, without any change in the genotype-risk factor relationship. Canalisation, therefore, can violate 
the exclusion restriction. 
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These different potential violations of Assumption 2 indicate that, as the specific functions of genetic 
variants and the mechanisms through which they affect individuals are often unknown, one can never claim 
that exclusion holds. Indeed, one can only test exclusion indirectly; we discuss this in more detail in section 
2.5 below.  
 
Assumption 3: Non-zero effect of the instrument on treatment 
A valid instrument must be associated with (i.e. have a non-zero effect on) the risk factor of interest. 
Mendelian randomization can only be used with genetic variants that have been robustly shown to affect 
the risk factor. This point is especially important, as many initial genotype-risk factor associations fail to 
replicate (Colhoun et al., 2003). Without a consistent population association, even if a sample correlation 
exists, Assumption 3 may be violated. Indeed, choosing SNPs merely based on the sample association with 
the risk factor (rather than using information external to the study) can lead to biased IV estimates (Taylor 
et al., 2014). It is therefore important that Mendelian randomization studies only use genetic variants that 
have been shown to be robustly associated with the risk factor in a large number of independent studies. 
However, even if a suitable genetic instrument is available, it may explain little of the variation in the 
observed risk factor. A weak association could result in a biased IV estimate and has implications for 
statistical power. If the alleles shift the distribution of risk factor by a very small amount, the effect of the 
risk factor on the outcome is identified only by this small difference, emphasizing the need either for very 
large sample sizes, especially when the average causal effect of the risk factor on the outcome could be 
small, or many genetic variants that can be combined into a more powerful instrument. This, of course, is 
not a problem specific to Mendelian randomization, but refers to a more general problem of weak 
instruments (see e.g. Bound et al., 1995; Staiger and Stock, 1997; Stock et al., 2002).  
 
Assumption 4: Monotonicity 
Whether monotonicity is satisfied relies on knowing each individual’s counterfactual and therefore 
always remains an assumption. Monotonicity may be violated in the presence of gene-environment 
interactions; i.e. when the effect of the environment on the risk factor differs depending on individuals’ 
genetic predisposition, or when individuals’ genetic predispositions are expressed differently in different 
environments. For example, if the expression of a genetic variant that increases fat mass depends on 
individuals’ awareness of the importance of nutrition for one’s health, monotonicity may be violated when 
the potential fat mass of an individual with the genetic variant in an (e.g. educated) environment is less than 
the potential fat mass for the same individual in that environment without the genetic variant. However, if 
the expression of the variant is simply reduced in the educated environment, monotonicity would not be 
violated, as the potential adiposity of an individual with the genetic variant remains at least as high as the 
potential adiposity for the same individual without the genetic variant.  
 
2.4 The Role of Covariates in Mendelian Randomization Experiments 
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There is a large literature on the use of covariates in IV. Economics and social applications of IV 
generally include a wide set of control variables; the main motivation being that the conditional independence 
and exclusion restriction are more likely to be valid. A second reason for including covariates in many 
economics and social applications of IV is that it may reduce the residual variability of the dependent 
variable, leading to more precise estimates.  
The situation is somewhat different, however, in RCTs/encouragement designs, and in Mendelian 
randomization studies. When covariates enter the assignment mechanism in RCTs/encouragement designs, 
such as when randomization takes place within certain strata, these covariates should be controlled for, 
relying on the conditional independence assumption. The inclusion of further baseline covariates may in 
addition increase the precision of the estimates. In Mendelian randomization studies, however, there are no 
baseline covariates. Furthermore, as covariates do not enter the assignment mechanism, assignment is 
independent of covariates, and we can rely on the unconditional independence assumption. Therefore, 
conditioning on covariates is not necessary in Mendelian randomization experiments. The exception, 
however, is when there is population stratification. In this case, the analyses should be done within 
population subgroups, or should adjust for principal components from genome wide data, relying on the 
conditional independence assumption.  
Although one may choose to adjust for covariates to increase precision, this raises the issue of which 
covariates to include in a Mendelian randomization study, as any characteristic is, in principle, a post-
treatment variable with respect to the instrument, and -with that- may be affected by the instrument. If the 
instrumented treatment has multiple causal effects, or if the outcome has a causal effect of its own, adjusting 
for such post-treatment variables may lead to biased estimates of the causal effect. Indeed, we should not 
control for any ‘downstream’ (behavioural) covariates that are potentially affected by the treatment or 
outcome. Thus, we only control for 10 ancestry-informative principal components in our main analyses, 
though we report the estimates that adjust for further covariates in the sensitivity analysis. Under 
independence, and when the instrumented treatment and outcome do not affect these covariates, the 
unadjusted and adjusted IV estimates should be similar, though the latter may be more precise. 
 
2.5 Testing the Exclusion Restriction 
There is no direct test for the validity of the exclusion restriction (Assumption 2). In other words, its 
validity will never be known with certainty and can only be examined indirectly or falsified by the data. To 
this end, however, Mendelian Randomization is no different from any other (non-genetic) IV study; the 
exclusion restriction always remains an assumption. However, one of the differences, one may argue, is that 
the specific functions of genetic variants and the mechanisms through which they affect individuals are 
often unknown, making it more difficult, if not impossible, to argue that the instrument is valid. However, 
with a rapidly growing medical literature, our knowledge on the specific function of variants is increasing. 
For example, much is now known about the function of certain variants in the metabolism of alcohol, 
leading to clear predictions from the medical literature on how they affect individuals’ alcohol consumption. 
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But knowing the exact function of a variant is not sufficient. Indeed, the variant may be pleiotropic, and its 
pleiotropic effects may have not yet have been identified, potentially invalidating the instrument.  
Similar to other IV studies that use multiple instruments, however, Mendelian randomization allows 
for potential violations through pleiotropy or LD (though not necessarily canalisation) to be tested when 
data is available on a large number of genetic instruments. More specifically, if multiple IV models - each 
using different combinations of these variants - predict the same causal effect, it is unlikely to be due to 
some common pleiotropy or LD across the different sets of variants, assuming that the different variants 
are located on different chromosomes and affect the trait via different pathways (Davey Smith, 2011; 
Palmer et al., 2011; von Hinke et al., 2013). Hence, consistency between such estimates provides evidence 
against potential pleiotropy or LD-induced confounding. However, obtaining different causal effects with 
different combinations of variants does not necessarily point to a violation of the exclusion restriction, as 
variability in treatment effects may occur due to different compliant subpopulations for the different 
instrument sets (i.e. different LATEs or CACEs). 
Alternatively, one can view Mendelian randomization with multiple instruments as analogous to a meta-
analysis of separate study results. Just like the IV estimate using multiple instrumental variables is a weighted 
average of the individual IV estimates, a meta-analysis is a weighted average of multiple studies. Bowden et 
al. (2015) show that, in this setting, Egger regression (a tool to detect small study bias in meta-analysis) can 
be adapted to test for bias from pleiotropy. In addition, it can provide an estimate of the causal effect of 
the treatment on the outcome of interest, even when the genetic variants are invalid.  
In a constant effects model, one can indirectly test whether the exclusion restriction holds using an 
‘over-identification’ (Sargan or Hansen) test (Sargan, 1958; Hansen, 1982), provided that there are more 
instruments than endogenous variables. Note, however, that this is not a test that the instruments are indeed 
valid. A problem with the over-identification test is that it has low power, especially when the underlying 
IV estimates are imprecise. In our heterogeneous treatment effects framework however, over-identification 
tests are inappropriate, even when the underlying estimates are precise, as a rejection of the test need not 
imply a violation of the exclusion restriction. As discussed above, it may point to treatment effect 
heterogeneity, as different valid instruments may estimate different parameters, with the final IV estimate 
being a weighted average of the different treatment effects. Hence, although we report the test statistic 
below, we cannot necessarily interpret it in a heterogeneous treatment effects framework.  
Note that, although canalisation refers to a violation of the exclusion restriction, it cannot necessarily 
be tested using over-identification tests. Similar to the above, a rejection cannot distinguish between 
treatment effect heterogeneity and canalisation. In fact, there is no (clear) way of testing or correcting for 
canalisation. However, for the complex traits that are largely of interest in Mendelian randomization studies, 
there is no evidence that canalisation occurs in humans (Davey Smith and Ebrahim, 2003). 
 
2.6 Previous Studies in the Economics Literature 
The existing economics literature includes three studies that exploit genetic variation to identify the 
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effects of BMI on economic outcomes. Ding et al. (2009) examine the effects of several health conditions, 
one of which is BMI, on adolescents’ academic achievement. Their IV results show large and significant 
negative effects on girls’ Grade Point Average (GPA), but not for boys. GPAs for obese girls are on average 
0.8 points lower than for non-obese girls. They use four genetic variants as instruments: the dopamine 
transporter (DAT1) and D2 receptor (DRD2), tryptophan hydroxylase (TPH) and cytochrome P4502B6 
(CYP2B6). Fletcher and Lehrer (2011) take a similar approach to Ding et al., but use the Add Health data 
to exploit within-family genetic inheritance. They find no evidence that obesity affects academic 
achievement. In addition to DAT1 and DRD2, their instruments include the dopamine D4 receptor 
(DRD4), the serotonin transporter (5HTT), monoamine oxidase (MAOA) and cytochrome P4502A6 
(CYP2A6). Finally, Norton and Han (2008) examine the effects of BMI on labour market outcomes using 
DAT1 and DRD4 as instruments for BMI and find no evidence of a causal association.  
The discussion in Section 2.3 above highlights the importance of the choice of genetic variants in 
Mendelian randomization experiments. Although the validity of the exclusion restriction can never be tested 
directly, it is unlikely that genes related to neurotransmitters such as dopamine receptors and serotonin 
transporters are valid instruments. The inherent problem is that neurotransmitters are implicated in many 
different neurological processes. Hence, it is difficult to argue that they can be used as valid instruments 
for one specific risk factor without being associated with others that could plausibly influence the outcome 
of interest (Cawley et al., 2011; von Hinke et al., 2011). 
More generally, however, Mendelian randomization can only be used with genetic variants that have 
been robustly shown to affect the risk factor (Assumption 4), relying on prior knowledge about the 
association between the genotype and risk factor. The choice of instruments in the studies cited above, 
however, seems to be data-derived: using either forward stepwise estimation (Ding et al.) or selecting those 
SNPs that have nominally statistically significant sample correlations in the first stage (Fletcher and Lehrer). 
Furthermore, both Ding et al. and Fletcher and Lehrer acknowledge that there is weak and inconsistent 
evidence in the medical literature, based on very small unrepresentative clinical samples, of the association 
between their genetic variants and health status or behaviours. Indeed, the IV strategy is invalid when 
relying only on such sample associations and leads to biased results (Taylor et al., 2014). Norton and Han 
(2008) base their selection of SNPs on a study by Guo et al. (2006), who find a negative association between 
the D4.7/D4.7 genotype of DRD4 and obesity. This relationship, however, has not been replicated in other 
independent studies (see for example Hinney et al. (1999), or Fletcher and Lehrer (2011) who find an 
insignificant but positive association; see also Lawlor, Windmeijer and Davey Smith, 2008).  
To our knowledge, there are no studies in economics that explore the effects of BMI on blood pressure. 
However, the relationship has been explored in the medical literature. Indeed, Timpson et al. (2009) use 
two genetic variants, FTO and MC4R, as instruments for BMI to explore the effects on blood pressure and 
hypertension risk. Using those aged 20 and over from the Copenhagen General Population Study, they find 
that BMI increases both systolic and diastolic blood pressure. We are, however, not aware of any studies 
exploring this relationship for children or adolescents.  
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3. Application: The Effect of Fat Mass on Academic Performance and Blood Pressure 
3.1 Data  
Our data are from a cohort of children born in one geographic area (Avon) of England. Women eligible 
for enrolment in the population-based Avon Longitudinal Study of Parents and Children (ALSPAC) had 
an expected delivery date between 1 April 1991 and 31 December 1992. Approximately 85% of these 
mothers enrolled, leading to about 14,000 pregnancies. The Avon area has approximately 1 million 
inhabitants and is broadly representative of the UK as a whole, though slightly more affluent than the 
general population.4 Detailed information on the study children and their families has been collected using 
a variety of sources, including self-completed questionnaires, data extraction from medical and educational 
records, in-depth interviews, and biological samples. Note however, that ALSPAC is a cohort; as such, 
there is no systematic data collection on siblings. 
A total of 12,620 children survived past the age of 1 and returned at least one questionnaire. Of these, 
we exclude 642 children because either their mother or father is of non-white ethnic origin (to avoid 
potential population stratification), leaving 11,978 potential participants. Our sample selection process is as 
follows. First, we select children for whom we observe their genotypes and 10 ancestry-informative 
principal components, leaving us with 7,335 children. Second, we drop children with missing data on fat 
mass. We further restrict the sample to children for whom we observe their educational outcomes and 
blood pressure, leading to a final sample size of 4,844 and 4,047 children respectively.  
Attrition in the ALSPAC cohort is known to be correlated with socio-economic position, with children 
from lower educated, lower income families more likely to drop out (Boyd et al., 2012; Fraser et al., 2012). 
Attrition can bias our analyses if observations are lost in a non-random manner. We explore attrition more 
generally in Table 1. Column 1 shows the descriptive statistics for the full sample of children for whom 
data is available. Column 2 shows the statistics for the sample with genetic information, and column 3 and 
4 use the final estimation sample for educational outcomes and blood pressure respectively. We confirm 
the socio-economic gradient in attrition: children in the estimation sample do significantly better in school, 
based on their Key Stage 3 (KS3) tests, their families are wealthier than the original sample, of higher socio-
economic position, and their mother are higher educated and older, with fewer mental health problems. 
Hence, there are considerable differences in the distribution of observables between the original and 
estimation samples. Note, however, that we find no evidence of any selection or non-random attrition 
based on genetic variants, whether we use an unweighted or weighted score, or the 32 individual variants. 
Furthermore, there are no significant differences in children’s blood pressure and fat mass between the 
different samples. Hence, although our analyses may be based on a selected sample of individuals, 
potentially limiting its generalisability, any attrition is unrelated to the genotypes used here. 
 
                                                 
4 For more information on the representativeness of ALSPAC, its enrolment and response rates, see Boyd et al., 2012; 
Fraser et al., 2012; and www.bristol.ac.uk/alspac 
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3.2 Measures of Academic Achievement, Blood Pressure, Fat Mass, and the Genetic Variants  
Our first outcome measure is the child’s Key Stage 3 (KS3) score. The KS3 exam is a nationally set 
exam, taken by all 14-year-olds in English state schools. This measure of children’s performance is therefore 
objective and comparable across all children. Their scores for three subjects (English, maths and science) 
are obtained from the National Pupil Database, a census of pupils in England in the state school system, 
which is matched into ALSPAC. We use an average score for the three subjects, standardised on the full 
sample of children for whom data is available, with mean 100, standard deviation 10.  
Our second outcome measure is the child’s blood pressure, measured in millimetres of mercury (mm 
Hg) at age 13. We observe both systolic (maximum) and diastolic (minimum) blood pressure, measured by 
trained nurses. Blood pressure was measured twice at the clinic; we use the average of the two readings to 
reduce measurement error. 
Our main measure for child fat mass, our risk factor of interest, is the child’s body fat mass (adjusted 
for age in months, height and height squared), as measured by a dual-energy X-ray absorptiometry scan 
(DXA) at age 11. As fat mass is measured two to three years prior to the outcomes of interest, this avoids 
potential problems related to reverse causation. The DXA scan scans the whole body, dividing it into fat, 
lean tissue, and bone mass. We standardise fat mass on the full sample of children for whom data are 
available, with mean 100 and standard deviation 10.  
For the genetic variants, we use 32 SNPs that have been consistently found to relate to body weight 
and fat mass (Speliotes et al., 2010; see below).5 There are different ways to include these instruments in 
our analyses, though each of these has potential drawbacks. For example, we may use the 32 variants or the 
64 adiposity-increasing alleles as separate instrumental variables, potentially leading to weak instrument bias, 
as the effect of each individual variant or allele on adiposity is small. Alternatively, we could use a count of 
the total number of risk alleles carried by each individual (an ‘allelic score’), increasing the strength of the 
instruments. However, this imposes an equal effect size for every allele, which is not necessarily supported 
by the data. Similarly, we could define multiple instruments as separate dummy variables indicating the 
number of risk alleles carried by each individual. Although this allows for different numbers of risk alleles 
to have different effect sizes, it assumes that the effect of carrying e.g. four risk alleles is the same no matter 
which four they are. We could also use a weighted allelic score, where the weights are defined by the effect 
size of each particular variant on adiposity, as estimated in an independent meta-analysis.  
The evidence suggests that allele scores give unbiased estimates and are more efficient than using the 
individual variants. There is some loss of power associated with an unweighted rather than weighted score, 
with the extent of the loss depending on the variation in effect sizes (see e.g. Pierce et al., 2010; Burgess 
                                                 
5 We discuss these in more detail below, as well as in the Web Appendix. In short, however, these are NRXN3 
(rs10150332), BDNF (rs10767664), GNPDA2 (rs10938397), LRRN6C (rs10968576), PRKD1 (rs11847697), GPRC5B 
(rs12444979), CADM2 (rs13078807), SLC39A8 (rs13107325), TNNI3K (rs1514175), PTBP2 (rs1555543), FTO 
(rs1558902), NUDT3 (rs206936), FLJ35779 (rs2112347), MAP2K5 (rs2241423), QPCTL (rs2287019), NEGR1 
(rs2815752), TMEM18 (rs2867125), LRP1B (rs2890652), KCTD15 (rs29941), TMEM160 (rs3810291), MTCH2 
(rs3817334), MTIF3 (rs4771122), ZNF608 (rs4836133), RPL27A (rs4929949), SEC16B (rs543874), MC4R (rs571312), 
RBJ (rs713586), FAIM2 (rs7138803), SH2B1 (rs7359397), FANCL (rs887912), ETV5 (rs9816226), TFAP2B 
(rs987237), where the rs-number is an identification tag that uniquely positions the polymorphism in the genome. 
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and Thompson, 2013; Davies et al., 2014). Furthermore, the evidence suggests that the bias properties of 
the weighted and unweighted scores are robust to mis-specifications of the score, such as the presence of 
gene-gene and gene-environment interactions, and the mis-measurement of weights in a weighted score 
approach (Burgess and Thompson, 2015). In our main analysis, we use an unweighted allelic score, 
increasing the power of the instruments and alleviating weak IV problems. However, we also explore the 
alternative specifications discussed above in the sensitivity analyses.  
  
3.3 Examining the Validity of the Genetic Variants in our Empirical Applications 
Using a total of 249,796 individuals from 64 different cohorts of European ancestry, Speliotes et al. 
(2010) conducted a large-scale GWAS meta-analysis. This confirmed 14 known obesity susceptibility loci 
and identified 18 new loci, with no evidence of non-additive effects, SNP*SNP interaction effects, or 
heterogeneity by sex or study. We use these 32 variants to explain variation in adiposity. We next relate the 
specific choice of these variants to the assumptions for suitable use of genetic variants as instruments 
discussed in Section 2.2 and 2.3.  
 
Assumption 1: Independence 
The independence assumption may be violated in the presence of population stratification due to 
ethnicity. For example, the allele frequencies of the SNP that accounts for the largest proportion of the 
variance (FTO) are known to vary by ethnic group (Frayling et al., 2007). Nevertheless, it is not likely to be 
a problem here, as our cohort is recruited from a specific geographically defined region with a 
predominantly white population. In addition, our analysis only includes children whose mother describes 
herself and the child’s father as white, and we adjust all analyses for 10 ancestry-informative principal 
components. Furthermore, we investigate whether there is any evidence of systematic variation in the 
covariates by genotype. Appendix B presents the results, exploring whether the distribution of covariates 
is the same across the instrument distribution. Although there are no true pre-randomization variables, and 
significant differences do not necessarily indicate violation of independence (see also section 2.3), we find 
no evidence of systematic differences for the different covariates, providing at least suggestive evidence of 
randomization of the genetic variants. 
 
Assumption 2: Exclusion  
The exclusion restriction may be violated in different situations. First, we note that those who carry the 
adiposity-increasing alleles of any of the variants used here do not necessarily become obese. The variants 
increase body weight by a modest amount, with the majority of effect sizes below 500g. In addition, as 
individuals do not know their genotype, parents are unlikely to notice the subtle difference in (children’s) 
size that is related to their genotype. Hence, it is unlikely to observe any strong responses to increased body 
weight, such as changing (children’s) diets. However, the question remains whether there are any more 
subtle responses to higher body weights. As it requires large sample sizes and data on different parental 
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preferences and behaviours to explore that in detail, one cannot say with complete certainty that behaviours 
are unaffected. Nevertheless, we explore this indirectly in our data, testing whether mothers’ behaviours or 
characteristics6 are related to their genotype. In the Web Appendix, Table S1, we explore whether the 
distribution of covariates is the same in groups defined by the mothers’ genotype, showing little evidence of 
systematic differences. This may be because there simply are no differences in maternal behaviours by 
genotype, because we lack sufficient power to detect any differences, or because we do not observe the 
behaviours that are affected by the genotype.  
Second, we searched for and examine existing literature related to the mechanism through which the 
variants may affect fat mass. Unfortunately, little is known about the physiological function of most of our 
variants, with much of this work ongoing in the medical literature. Nevertheless, there is evidence that some 
variants (FTO, MC4R) are associated with an increased consumption of fat and energy (see e.g. Timpson 
et al., 2008; Cecil et al., 2008, Richmond and Timpson, 2012). The literature suggests that the SNPs increase 
food intake due to diminished satiety (Wardle et al., 2008), rather than through pathways that affect our 
outcomes of interest. Table S2 in the Web Appendix briefly lists what the 32 variants used here have been 
shown to be associated with. Although the vast majority of associations are with adiposity-related 
phenotypes, we note that the variants are likely to be associated with additional phenotypes not shown in 
the Table, either because studies that have explored these associations were underpowered, or because 
studies have not (yet) investigated those relationships. Depending on these additional associations, they 
may invalidate their use as instruments if they affect the outcome of interest directly. Nevertheless, our 
current knowledge suggests that, in addition to being related to adiposity and adiposity-related phenotypes 
(such as Type II diabetes), some variants have been shown to be associated with allergic asthma and rhinitis 
(rs10767664), hyperactivity/impulsivity (rs1307880, rs2241423), schizophrenia (rs10150332 and 
rs13107325), inattention (rs206936), white matter integrity (rs2815752), and Alzheimer disease risk 
(rs4836133, rs713586).7 We explore the robustness of our results to excluding these variants from the 
instrument set in the sensitivity analyses below. 
Third, pleiotropy or LD would bias the IV estimates if the variant affects the outcome directly or if the 
linkage is with another variant that directly affects our outcomes of interest. We explore maps of the human 
genome to investigate LD, and find no evidence that the variants used here directly affect (or are in LD 
with variants that directly affect) our outcomes of interest or its determinants. More specifically, data from 
the International HapMap Project show that the SNPs that replicate in a large number of independent 
samples for educational attainment (Rietveld et al., 2013) and blood pressure (Ehret et al., 2011) are not in 
LD with those for fat mass (Speliotes et al., 2010).  
Fourth, for canalisation to violate the exclusion restriction, the presence of the fat related variant at 
                                                 
6 Including her education, age, lone parenthood, employment, smoking, drinking, duration of breastfeeding, locus of 
control, a ‘teaching score’, and two scores indicating her engagement with and interest in outdoor, and in indoor 
activities with the child. 
7 The associations with hyperactivity, impulsivity, and inattention were not replicable in independent samples. For 
more information, see the Web Appendix. 
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conception would have to result in different brain or blood vessel development in order to counter any 
predicted adverse effect of fat mass on the outcome. We believe this is implausible. Furthermore, there is 
no evidence in humans that canalisation occurs in relation to complex traits such as fat mass. 
In summary, we do not know individuals’ behavioural response to their genotype, the specific 
physiological functions or biological pathways through which the variants affect the phenotype, and 
whether the variants have multiple phenotypic effects. With that, it is impossible to guarantee that 
Assumption 2, exclusion, holds. For instance, it is possible that some variants’ pleiotropic effects have 
simply not yet been identified, or that there are other variants that are in LD with our instruments that 
affect the outcomes of interest, but have not yet been identified. Hence, similar to any other IV approach, 
exclusion remains an assumption, as we cannot test for this directly.  
 
Assumption 3: Non-zero effect of the instrument on treatment  
The prior findings of robust associations between the genetic variants and fat mass, replicated in a large 
number of studies, justify their use as instruments. Using standard statistical tests, we will examine the 
strength of our instruments in the application below.  
 
Assumption 4: Monotonicity 
Finally, with random allocation of genetic variants and the fact that individuals do not know their genotypes, 
we assume that an individual who carries the risk allele is at least as heavy as the same individual, had she 
not carried the risk allele, satisfying monotonicity. Although we do not observe individuals’ counterfactuals, 
the literature tells us that, at a group or population level, those who possess the genetic variants are heavier 
than those who do not.  
As monotonicity can be violated by gene-environment interactions, we examine this in two ways. First, 
we explore the issue of such interactions indirectly, testing whether the association between fat mass and 
our instrument differs in different ‘environments’. Although one can never observe all potentially relevant 
gene-environment interactions, we explore the importance of a set of environments that have been shown 
to be important for child development, defined by gender, the child’s birth weight, breastfeeding duration, 
social class, mother’s education, income and deprivation. The results (presented in Table S3 in the Web 
Appendix) show little evidence of gene-environment interactions.  
Second, we study the existing literature on gene-environment interactions for fat mass. Kilpeläinen et 
al. (2011) find some evidence of such interactions between FTO and physical activity, though only for 
adults: for the physically active, the FTO risk allele increases the odds of obesity less than for the physically 
inactive. They do not find such interaction for children. Using a sample of around 170,000 individuals, a 
recent study explores whether genetic variants explain the variance of BMI (as opposed to the mean, as gene-
environment interactions by construction lead to variance inflation). They conclude that there are no 
common genetic variants that account for a large proportion of variation in environmental or phenotypic 
variability, finding no evidence of widespread gene-environment interaction effects for BMI (Yang et al., 
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2012).  
 
3.4 Descriptive Statistics  
Table 2 presents the mean adiposity for each of the 32 SNPs, distinguishing between those who are 
homozygous for the adiposity non-increasing allele, heterozygous, and homozygous for the adiposity-
increasing allele. This shows that each of the individual SNPs explain little of the variation in adiposity, 
leading to low power in the IV analysis. Rather than using each of the individual SNPs, we therefore use an 
allelic score, defined as the count of the number of adiposity-increasing alleles. As we show below, this 
explains a larger proportion of the variance in adiposity than the individual SNPs, increasing the power of 
the instrument. In the sensitivity analyses (Section 3.6), however, we also show the results using different 
specifications of the instrument, including the 32 individual SNPs, the 64 alleles, and a weighted allelic 
score.  
Figure 1 shows a histogram of the number of adiposity-increasing alleles carried by each child, showing 
a bell-shaped distribution. On average, children carry 29 adiposity-increasing alleles (standard deviation = 
3.4), with the total number ranging between 14 and 42.  
 
3.5 Results  
Table 3 presents the results. Panel A, columns 1 to 3 show the association between fat mass and the 
KS3 score, systolic, and diastolic blood pressure, conditional on the 10 principal components. The 
relationship between fat mass and educational attainment is negative, with a one standard deviation increase 
in fat mass associated with a 0.09 standard deviation decrease in test scores. Columns 2 and 3 show a 
positive association for blood pressure, with a one standard deviation increase in fat mass associated with 
a 0.23 and 0.12 mm Hg increase in systolic and diastolic blood pressure respectively; similar to 
approximately 0.02 of a standard deviation. 
Panel B presents the first-stage regression results, showing a strong positive relationship between the 
instrument and child fat mass. The strength of the relationship is shown by the first stage F-statistic. A 
value of 76 (KS3) and 69 (blood pressure) suggests the instrument is strong. Translating the effect size into 
body weight, a one standard deviation increase in the allelic score increases weight by around 1.3 to 1.5 kg, 
though the exact amount will depend on which alleles are carried by the individual, as there is much 
heterogeneity in the variants’ effect sizes on adiposity. For example, each risk allele of FTO – the variant 
that has been shown to have the largest effect size – increases body weight by approximately 1kg for an 
average 11 year old, whereas the effect size for GNPDA2 increases body weight by just over 300g. 
The second stage IV results are presented in Panel C. Colum 1 shows no effects of fat mass on 
educational performance. Although the IV estimate is of similar magnitude but opposite sign to that in 
Panel A, the large standard errors preclude us from rejecting the null of no effect. However, with a p-value 
of 0.054 for the Hausman test, there is some support for the IV as opposed to the OLS estimate, though 
any such judgement should be based on a synthesis of all the evidence, rather than on this one test alone.  
22 
 
Column 2 and 3 show a positive effect of fat mass on both systolic and diastolic blood pressure, with 
an estimate that is somewhat larger than the OLS estimates in Panel A. The estimates suggest that a one 
standard deviation increase in fat mass increases systolic and diastolic blood pressure by 0.37 and 0.21 mm 
Hg respectively, though the Hausman test suggests that there is insufficient evidence to reject the hypothesis 
that the OLS estimate is unbiased.  
 
3.6 Sensitivity Analyses  
We next report a set of sensitivity analyses, evaluating the robustness of the results. First, we use 
different specifications of the instrument. We start by specifying the 28 mutually exclusive instruments, 
indicating the number of adiposity-increasing alleles carried by each child. Panel A of Table 4 presents the 
results, showing no effect of adiposity on KS3, but a positive effect on both systolic and diastolic blood 
pressure. The over-identification (Hansen J) test does not reject the null. However, as discussed above, it 
is difficult to interpret this in a heterogeneous treatment effects framework, as a rejection may simply point 
to treatment effect heterogeneity.  
Panel B of Table 4 uses the 32 independent genetic variants as 32 instrumental variables. Panel C 
specifies the number of adiposity-increasing alleles for each variant as separate instruments (i.e. 64 
instruments), and Panel D uses a weighted allelic score. The latter is similar to the count of the number of 
risk alleles, but incorporates the fact that the variants have different effect sizes. Indeed, although the bias 
properties of the unweighted score have been shown to be robust to mis-specification (e.g. due to mis-
measurement of weights, gene-gene or gene-environment interactions), it leads to a loss of power. We 
therefore use a weighted allelic score, where the weights at each locus are defined by the effect size of the 
variant on adiposity, estimated in an independent meta-analysis (Speliotes et al., 2010). Despite the different 
instrument specifications and their strength in the first stage as shown by the F-statistic, the results are 
similar. 
As discussed in section 3.3, some of the variants in our analyses have been shown to associate with 
other, non-adiposity related, phenotypes, such as asthma and schizophrenia. In Panel E, we re-estimate the 
IV model with the weighted IV score that drops these variants (see Web Appendix) from the instrument 
set. In addition, Panel F shows the estimates using only FTO and MC4R, the two variants that account for 
the largest proportion of the variation in fat mass, as the instrumental variables. The estimates are similar, 
suggesting that the findings are not sensitive to the definition and specification of the instruments.8 
Second, we explore the potential problem of weak instruments in more detail, using the critical values 
in Stock and Yogo (2005). Although the weighted and unweighted allelic scores show strong first stage 
results, the F-statistic of approximately 8, 4 and 3 in Panels A, B and C of Table 4 respectively, imply that 
the relative bias of the IV estimates is between 10% and 20% (Panel A) and over 30% (Panels B and C), 
and the size distortion over 25%. We therefore compare these estimates to different estimators that suffer 
                                                 
8 The results in Panel E and F that use a restricted instrument set are also robust to using an unweighted score, or 
using the variants/alleles separately as instruments. 
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less from weak instrument bias, using LIML and Fuller-k (with k=1). The critical values in Stock and Yogo 
(2005) show that, for example, with 27 instruments and a first stage F-statistic of 8.3, the size distortion in 
LIML is less than 10%, and Fuller has a relative bias that is less than 5%. We present the LIML and Fuller(1) 
results for our specification with the largest number of instruments (i.e. 64 instruments, as in Panel C of 
Table 4) in Table 5, showing similar estimates for the different estimators, suggesting that our results are 
not driven by weak instruments.  
Third, we explore different definitions of the variable of interest: fat mass. As we discuss in the 
introduction, obese children may have different educational outcomes due to sleep disorders, school 
absenteeism, or differential treatment by teachers, parents and peers. This would suggest that there may be 
non-linearities. Hence, it is of interest to study whether there are substantially different effects on education 
and blood pressure for underweight and overweight children. We examine the child’s underweight and 
overweight status in the IV analysis, defined as being in the bottom and top 15th percentile of the fat mass 
distribution respectively. We show the results using the (unweighted) allelic score as our instrumental 
variable, though they are robust to using the different instrument specifications. The results are presented 
in Table 6, with panel A showing the estimates of being underweight, and panel B presenting the effects 
for being overweight. These show that the instruments are somewhat less predictive of both binary 
indicators. However, with a first stage F-statistic ranging between 18 and 45, it is sufficiently strong, and 
the results show a similar pattern to those above. For Key Stage 3 (column 1), their imprecision means we 
cannot reject the null of no effect. For blood pressure (columns 2 and 3), the estimates confirm that being 
underweight substantially decreases both systolic and diastolic blood pressure, whilst being overweight leads 
to an increase. 
Next, we explore the existence of heterogeneous effects of fat mass on KS3 and blood pressure by 
gender. It may be, for example, that girls are more affected by potential peers’ differential treatment related 
to their adiposity than boys. Table 7, Panels A and B, present the results, showing a larger (positive) effect 
of adiposity on educational attainment for girls than boys, though both remain insignificantly different from 
zero. We also find an increase in systolic blood pressure for both boys and girls, though no significant effect 
on diastolic blood pressure for boys. Although we are not the first to find such gender differences (see e.g. 
Doll et al., 2002), the reasons for the differential effects by gender are unknown, with some suggesting it 
may be due to gender differences in the body fat distribution (Janssen et al., 2004). 
Finally, we examine the robustness of the estimates to the inclusion of different sets of covariates. As 
we argue in Section 2.4, our main analysis does not control for any covariates other than the 10 principal 
components, as any covariates are measured post-randomization and, with that, may be affected by the 
treatment or outcome. However, one could argue that some covariates are determined prior to, or at the 
time of, conception, such as child gender and some parental characteristics. Controlling for these covariates 
may therefore increase the precision of the estimates. Table 8 presents the results controlling for the child’s 
gender (Panel A), for gender, maternal educational attainment, paternal social class, and the Index of 
Multiple Deprivation, measured at birth (Panel B), and for the full set of background characteristics 
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mentioned in Appendix B (Panel C). We specify the (unweighted) allelic score as the instrumental variable. 
All findings are similar to the initial estimates: the large standard errors mean we cannot reject the null of 
no effect on the Key Stage 3 outcome, but we find strong positive effects on blood pressure. The confidence 
interval becomes slightly narrower when we control for the full set of characteristics, but it does not affect 
the interpretation of the findings. Taken together, these analyses show no evidence that children’s fat mass 
affects their academic performance, but that increased fat mass leads to a rise in blood pressure.  
 
4. Conclusion and Discussion 
Economists have become increasingly interested in the effects of behaviours such as smoking, drinking 
or excessive food intake on economic outcomes. As these behaviours are endogenous and difficult (if not 
impossible) to randomize in an RCT, estimating their effects is difficult. Many studies therefore attempt to 
find instrumental variables, or exploit some natural experiment that shifts the behaviour for some group, 
but not others, to identify their causal impact. The increasing availability of biomedical data, in combination 
with a growing medical literature on the effects of carrying specific genetic variants, introduces a different 
approach to the examination of certain risk factors on different outcomes. This paper discusses the method 
of instrumental variables using Mendelian randomization, and links this to the statistical potential outcomes 
framework. Mendelian randomization provides a novel approach to estimating the causal impact, and with 
that will be of interest to economists to explore.   
We note that its suitability and applicability depends on a set of (biological) conditions, as well as on 
the research question and context. We discuss the specific conditions that need to be met for genetic 
variants to be used as instruments, and relate these to the statistical assumptions necessary for identification 
of the average causal response using instrumental variables. These conditions have not been well defined 
in the current social science literature, but understanding them is crucial to the appropriate use of genotypes 
as instruments for modifiable risk factors.  
We review these conditions in the context of two empirical applications. First, we examine whether 
child fat mass causally affects academic achievement, and second, we study whether it affects blood 
pressure. To study the effect of adiposity on our outcomes of interest, a well-conducted RCT would 
randomize an intervention that reduces fat mass and compare the outcomes between the group that was 
treated and the control group. Randomizing adiposity, however, is difficult. We show that, in such cases, 
quasi-experimental designs such as Mendelian randomization experiments can provide an interesting 
alternative approach. We use a set of 32 recently identified genetic variants as instrumental variables for fat 
mass to illustrate the key concepts. In these illustrative examples, we show the systematic approach required 
to identify genetic variants as instruments. We also use direct measures of fat mass, rather than the generally 
used BMI. OLS shows that leaner children perform better in school tests compared to their fatter 
counterparts, and that fatter children have higher blood pressure. Our genetic IV analysis, however, shows 
no evidence that children’s fat mass affects their academic performance, whilst we find that fat mass 
increases children’s blood pressure. 
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Our discussion of the conditions for the suitability of genetic variants as instrumental variables and our 
application raise some more general issues of the use of genetic variants as instruments. First is the question 
whether genetic variants are powerful enough to identify causal effects. In the illustrative case we examine, 
while our instruments are not weak in a statistical sense their effects may be too small to impact on the 
possible pathways to academic performance. In other words, a 1-2 kg increase in fat mass may not lead to 
a large drop in self-esteem or an increase in absenteeism. It is, therefore, perhaps not surprising that we 
find no significant effect on academic performance. In contrast, our results on blood pressure show strong 
evidence of an increase driven by elevated fat mass. As intervention studies of weight reduction (see e.g. 
the meta-analysis of randomized controlled trials by Neter et al., 2003) have shown that a 5 kg weight loss 
is sufficient to cause a reduction in systolic blood pressure of about 4 mm Hg, this suggests that even small 
changes in fat mass, such as those driven by genetic variants, can identify changes in blood pressure with 
sufficient precision (see also Timpson et al., 2009).  
Hence, if small changes in the risk factor are sufficient to shift the outcome of interest, Mendelian 
randomization presents an interesting approach. However, if the outcome of interest is only affected by 
large changes in the risk factor, Mendelian randomization may not be sufficiently powerful, as genetic 
variants generally shift the risk factor by a relatively small amount. This is particularly relevant for studies 
in economics, which are often interested in the effects of different intermediate phenotypes (e.g. adiposity, 
smoking, drinking) on economic outcomes. In contrast to various examples in the medical literature, finding 
effects on such economic outcomes generally requires larger changes in the risk factor. With most genetic 
variants having small effect sizes, this suggests they explain insufficient variation in the risk factor to affect 
the outcome of interest. With a rapidly growing medical literature on the effects of carrying specific variants, 
one option is to wait for more variants to be identified and to combine these into one a (weighted) count 
of the number of risk alleles. This could increase the explained phenotypic variation and with that, the 
precision of the estimates. But for the type of physical attributes that economists have been interested in 
such as fat mass or height, any additional variants are likely to have even smaller effects than those already 
identified.9  
A second issue is the credibility of the IV assumptions. Some of these are testable, but others are not. 
In particular, the validity of the exclusion restriction cannot be tested, and will never be known with 
certainty, which makes Mendelian randomization a controversial approach within the economics literature. 
Our paper has discussed this in detail and highlighted the various ways through which the use of genetic 
variants as instrumental variables may lead to invalid inferences. With our limited understanding of the 
functions of variants and the pathways through which they affect outcomes, it is unlikely that we will 
understand their exact function and mechanism in the foreseeable future. Hence, we argue that genetic 
variants need to be used with care. Their appropriate use requires that several conditions, which have not 
hitherto been spelt out in the economics literature, are met. However, even if these conditions are met, the 
                                                 
9 For example, the most recent (at time of writing) GWAS identified an additional 56 BMI-associated loci, which 
generally have lower minor allele frequency and/or smaller effect size estimates than previously known loci (Locke et 
al., 2015). 
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sample sizes in data sets that contain both genetic markers and outcomes of interest to economists may be 
too small to obtain definitive results. Indeed, even with around 4000-5000 observations, our standard errors 
are relatively large. But with a rapid increase in the number of genome wide association studies, and with a 
decrease in their costs, this may change. Finally, just as there are good and poor RCTs and studies using 
any other identification design and methodology, there are good and poor Mendelian randomization 
studies. By highlighting the potential problems and showing the systematic approach required to identify 
genetic variants as instruments, we attempt to steer others to carefully consider the different assumptions 
and conditions needed for valid inference before jumping to their use.  
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Appendix A: A Brief Introduction to Genetics 
Each cell in the human body contains a nucleus in which most DNA (99.9995%) is kept. DNA is stored 
in structures called chromosomes, where each chromosome contains a single continuous piece of DNA. 
All cells in the human body apart from germ cells contain 46 chromosomes, organised into 23 chromosome 
pairs: one copy of chromosome 1-22 from each parent, plus an X-chromosome from the mother and either 
an X or a Y chromosome from the father.  
Locations (or loci) where DNA varies between people are called polymorphisms. The most commonly 
studied form of polymorphism is a Single Nucleotide Polymorphism (SNP): a single base-pair variation in 
a DNA locus. As chromosomes come in pairs, humans have two base-pairs at each locus, called alleles. 
These alleles can either be the same or different. The term genotype is used to describe the specific set of 
alleles inherited at a particular chromosome locus. For example, individuals can have one of three genotypes 
of FTO: they can be homozygous for the common allele (TT), heterozygous (AT), and homozygous for 
the rare allele of FTO (AA). The visible or measurable effect of a particular genotype is called the phenotype. 
The phenotype, or risk factor, we examine is fat mass.  
Many studies have examined the heritability of fat mass, defined as the proportion of the total variance 
that is explained by genetic factors. These are most commonly calculated from twin studies, comparing 
intra-pair correlations for a characteristic in monozygotic twins with that in dizygotic twins. These studies 
generally report large heritability estimates: between 0.4 and 0.7. A high heritability however, does not imply 
that any individual genetic variant has large phenotypic effects. For example, there are many SNPs that 
affect human weight, though all with small effects: so-called ‘polygenes’. Together, these variants may have 
a large phenotypic effect. 
Until recently, researchers mainly used a ‘candidate gene approach’ to examine associations between 
individual genetic variants and a risk factor. This approach consists of testing a specific hypothesis: based 
on biological knowledge, researchers examine the association between one particular variant (the candidate 
genetic variant) and a risk factor. These studies produced many false-positive findings (Colhoun et al., 2003) 
and were inefficient. Genome wide association studies (GWAS) followed, genotyping 500,000 to over 
1,000,000 SNPs in one go and relating all SNPs to the risk factor of interest in a hypothesis-free way. 
Stringent criteria are used for GWAS p-values to take account of this hypothesis-free approach. Studies are 
either two-stage studies, where one or more GWAS is performed, after which the small number of SNPs 
that reach GWAS levels of statistical significance are typed in other independent samples to examine the 
robustness. Alternatively, studies consist of a number of independent GWAS containing a large total sample 
size, where only those SNPs that have consistent associations across all studies are interpreted as robust.  
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Appendix B: Indirect Test of Independence of Covariates and Genetic Variants 
Table B1 presents the coefficients (standard errors) of a regression of the covariate in the first column 
on the unweighted allelic score (columns 1 and 2) or weighted allelic score (columns 3 and 4). The final 
column shows the p-value of an F-statistic testing whether the coefficients on the 32 independent variants 
jointly equal zero. With random assignment of the genetic variants, there should be no systematic variation 
in the covariates by genotype. Although some coefficients are significantly different from zero, there is no 
evidence of systematic differences for the different covariates, providing at least suggestive evidence of 
randomization of genetic variants. 
 
Table B1: An indirect test of independence: regressing the covariate on the instruments 
 Unweighted allelic score 
 
Weighted allelic score 32 independent variants 
 Coefficient Standard 
error 
Coefficient Standard 
error 
p-value of F-test: 
instrument-coefficients 
jointly equal to zero 
Girl 0.00 (0.00) 0.00 (0.01) 0.560 
Birth weight (g) 2.62 (2.18) 19.22 (14.11) 0.550 
Age at KS3 (in months) 0.04*** (0.02) 0.16 (0.10) 0.341 
Ln(income) 0.00 (0.00) 0.00 (0.01) 0.392 
Mother’s education -0.00 (0.00) -0.00 (0.02) 0.341 
Raised by natural father 0.00 (0.00) 0.00 (0.01) 0.731 
Social class at birth -0.00 (0.01) -0.03 (0.03) 0.076 
Mum works part-time 0.00 (0.00) -0.01 (0.01) 0.971 
Mum works full-time -0.00 (0.00) -0.00 (0.01) 0.428 
Partner employed 0.00 (0.00) 0.01 (0.01) 0.905 
Index of Multiple Deprivation -0.06 (0.06) 0.32 (0.37) 0.259 
Alcohol during pregnancy 0.00 (0.00) 0.01 (0.01) 0.596 
Smoke during pregnancy  0.00 (0.00) 0.00 (0.01) 0.697 
Breastfeeding 0.00 (0.00) 0.00 (0.03) 0.080 
Mother’s age at birth 0.00 (0.00) -0.00 (0.02) 0.076 
Notes: * p<0.1; ** p<0.05; *** p<0.01; The p-value in the last column corresponds to an F-test of the coefficients on the 32 
instrumental variables jointly equalling zero; Ln(income) is measured when the child is aged 3-4 as is in 1995 prices; mother’s 
educational level is a categorical variable with four values (less than ordinary (O) level, O-level, advanced (A) level, and university 
degree); social class is measured using the standard UK classification of class based on occupation (professional (I), managerial and 
technical (II), non-manual skilled (IIInm), manual skilled (IIIm), semi-skilled (IV) and unskilled (V)); the Index of Multiple 
Deprivation (IMD) is a measure of local area deprivation, measured at birth, referring to areas containing about 8000 persons; 
breastfeeding is a categorical variable (never, <1 month, 1-3 months and 3+ months); the sample contains 4,846 observations. 
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Figures and Tables  
 
Figure 1: Distribution of the number of adiposity-increasing alleles carried by each child 
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Table 1: Mean and standard deviation (SD) of adiposity for each SNP.  
 Original sample Genetic sample Estimation sample 
(KS3) 
Estimation sample 
(BP) 
Outcomes Mean SD Mean SD Mean SD Mean SD 
KS3 100 (10.0) 101*** (9.6) 103*** (8.9) 104*** (8.8) 
Systolic BP 111 (11.5) 111 (11.3) 111 (11.2) 111 (11.2) 
Diastolic BP 56.3 (8.39) 56.2 (8.28) 56.2 (8.28) 56.2 (8.28) 
         
Treatments         
Fat mass 100 (10.0) 100 (9.8) 100 (9.8) 100 (9.7) 
         
Instruments         
Unweighted score 28.9 (3.47) 28.9 (3.5) 28.9 (3.45) 28.9 (3.44) 
Weighted score 4.02 (0.53) 4.02 (0.53) 4.02 (0.53) 4.02 (0.53) 
NRXN3 0.42 (0.57) 0.42 (0.57) 0.42 (0.58) 0.42 (0.57) 
BDNF 1.59 (0.58) 1.59 (0.58) 1.59 (0.58) 1.60 (0.57) 
GNPDA2 0.87 (0.70) 0.87 (0.70) 0.86 (0.69) 0.86 (0.69) 
LRRN6C 0.63 (0.65) 0.63 (0.65) 0.63 (0.65) 0.63 (0.65) 
PRKD1 0.09 (0.30) 0.09 (0.30) 0.09 (0.30) 0.10 (0.30) 
GPRC5B 1.73 (0.49) 1.73 (0.49) 1.73 (0.49) 1.73 (0.49) 
CADM2 0.40 (0.57) 0.40 (0.57) 0.40 (0.57) 0.40 (0.57) 
SLC39A8 0.15 (0.37) 0.15 (0.37) 0.14 (0.36) 0.15 (0.37) 
TNNI3K 0.85 (0.70) 0.85 (0.70) 0.85 (0.70) 0.85 (0.70) 
PTBP2 1.18 (0.70) 1.18 (0.70) 1.18 (0.70) 1.19 (0.69) 
FTO 0.81 (0.69) 0.81 (0.69) 0.81 (0.70) 0.82 (0.70) 
NUDT3 0.39 (0.56) 0.39 (0.56) 0.39 (0.56) 0.39 (0.56) 
FLJ35779 1.28 (0.67) 1.28 (0.67) 1.27 (0.67) 1.27 (0.67) 
MAP2K5 1.57 (0.58) 1.57 (0.58) 1.57 (0.58) 1.57 (0.58) 
QPCTL 1.62 (0.56) 1.62 (0.56) 1.62 (0.56) 1.62 (0.56) 
NEGR1 1.20 (0.69) 1.20 (0.69) 1.19 (0.69) 1.18 (0.69) 
TMEM18 1.66 (0.53) 1.66 (0.53) 1.66 (0.53) 1.66 (0.53) 
LRP1B 0.34 (0.53) 0.34 (0.53) 0.34 (0.53) 0.33 (0.53) 
KCTD15 1.37 (0.66) 1.37 (0.66) 1.37 (0.65) 1.38 (0.65) 
TMEM160 1.39 (0.64) 1.39 (0.64) 1.38 (0.64) 1.39 (0.64) 
MTCH2 0.80 (0.69) 0.80 (0.69) 0.80 (0.70) 0.80 (0.69) 
MTIF3 0.46 (0.59) 0.46 (0.59) 0.46 (0.59) 0.47 (0.59) 
ZNF608 0.99 (0.71) 0.99 (0.71) 0.99 (0.71) 0.99 (0.71) 
RPL27A 1.08 (0.70) 1.08 (0.70) 1.09 (0.70) 1.10 (0.70) 
SEC16B 0.42 (0.58) 0.42 (0.58) 0.42 (0.58) 0.42 (0.58) 
MC4R 0.47 (0.60) 0.47 (0.60) 0.47 (0.60) 0.47 (0.60) 
RBJ 0.98 (0.71) 0.98 (0.71) 0.98 (0.71) 0.98 (0.71) 
FAIM2 0.72 (0.68) 0.72 (0.68) 0.72 (0.68) 0.72 (0.67) 
SH2B1 0.83 (0.70) 0.83 (0.70) 0.82 (0.70) 0.82 (0.70) 
FANCL 0.58 (0.65) 0.58 (0.65) 0.58 (0.64) 0.58 (0.65) 
ETV5 1.65 (0.54) 1.65 (0.54) 1.65 (0.53) 1.66 (0.53) 
TFAP2B 0.36 (0.54) 0.36 (0.54) 0.36 (0.54) 0.36 (0.54) 
         
Covariates         
Girl 0.48 (0.50) 0.49 (0.50) 0.51*** (0.50) 0.52*** (0.50) 
Birth weight 3404 (557.2) 3439*** (532.1) 3436*** (525.7) 3438*** (521.6) 
Age at KS3 (in months) 170 (3.73) 170 (3.77) 170 (3.68) 170 (3.71) 
Ln(income) 5.29 (0.49) 5.33*** (0.48) 5.35*** (0.46) 5.37*** (0.46) 
Mother’s education         
  O-level 0.45 (0.50) 0.44 (0.50) 0.44 (0.50) 0.44* (0.50) 
  A-level 0.22 (0.42) 0.25*** (0.43) 0.26*** (0.44) 0.27*** (0.45) 
  University degree 0.12 (0.33) 0.15*** (0.35) 0.16*** (0.37) 0.17*** (0.38) 
Not natural father 0.92 (0.28) 0.93** (0.26) 0.93*** (0.25) 0.94*** (0.24) 
Father’s social class       ***  
  Managerial 0.34 (0.47) 0.36** (0.48) 0.36*** (0.48) 0.37 (0.48) 
  Non-manual skilled 0.12 (0.33) 0.12 (0.33) 0.13* (0.34) 0.13*** (0.34) 
  Manual skilled 0.31 (0.46) 0.29*** (0.45) 0.29 (0.45) 0.28*** (0.45) 
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  Semi-skilled 0.10 (0.30) 0.09* (0.29) 0.08*** (0.27) 0.08*** (0.27) 
  Unskilled 0.03 (0.17) 0.02* (0.15) 0.02*** (0.14) 0.02*** (0.14) 
Mum works part-time 0.36 (0.48) 0.38* (0.48) 0.38*** (0.49) 0.39*** (0.49) 
Mum works full-time 0.10 (0.30) 0.11 (0.31) 0.11** (0.32) 0.11** (0.32) 
Partner employed 0.88 (0.33) 0.89*** (0.31) 0.89 (0.32) 0.89 (0.32) 
IMD 20.8 (14.9) 19.7*** (14.4) 18.7*** (13.7) 18.6*** (13.6) 
Alcohol in pregnancy 0.55 (0.50) 0.56 (0.50) 0.57** (0.49) 0.58*** (0.49) 
Smoke in pregnancy  0.24 (0.43) 0.21*** (0.41) 0.17*** (0.38) 0.16*** (0.37) 
Breastfeed <1 month 0.16 (0.37) 0.16 (0.36) 0.16 (0.37) 0.15 (0.36) 
Breastfeed 1-3 months 0.16 (0.36) 0.16 (0.36) 0.16 (0.37) 0.16 (0.37) 
Breastfeed 4+months 0.42 (0.49) 0.47*** (0.50) 0.50*** (0.50) 0.51*** (0.50) 
Mother’s age: 20-24 0.18 (0.39) 0.16*** (0.37) 0.13*** (0.34) 0.13*** (0.33) 
Mother’s age: 25-29 0.40 (0.49) 0.39 (0.49) 0.40 (0.49) 0.40 (0.49) 
Mother’s age:30-34 0.28 (0.45) 0.31*** (0.46) 0.33*** (0.47) 0.34*** (0.47) 
Mother’s age: 35+ 0.10 (0.30) 0.11** (0.31) 0.12*** (0.33) 0.12*** (0.33) 
EPDS score 6.88 (4.83) 6.68*** (4.69) 6.45*** (4.56) 6.34*** (4.51) 
CCEI score 13.2 (7.78) 12.8*** (7.51) 12.6*** (7.31) 12.4*** (7.22) 
         
Sample size 11978 7335 4844 4047 
Notes: Family income is an average of two observations (when the child is aged 3 and 4) and is in 1995 prices. It is 
adjusted for family size and composition (equalised) using the OECD equivalence scale to allow for a comparison of 
incomes for all households. The social class variables use the standard UK classification of social class based on 
occupation (professional, managerial/technical, non-manual skilled, manual skilled, semi-skilled and unskilled). IMD 
refers to the Index of Multiple Deprivation, and provides a relative measure of deprivation at small area level. EPDS 
and CCEI refer to the mother’s Edinburgh Postnatal Depression Score and the Crown-Crisp Experimental Index. 
EPDS indicates to what extent the mother is at risk of perinatal depression; CCEI captures a broader definition of 
mental health, measuring general anxiety, depression and somaticism. Higher scores mean the mother is more affected. 
The descriptive statistics for the full sample, Column (1), are based on a maximum of 11,978 observations if the 
variable reported in the column has no missing values on any observations. * p<0.10, ** p<0.05, *** p<0.01 refers to 
a test whether the mean is significantly different from the mean in the original sample shown in Column 1. 
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Table 2: Mean and standard deviation (SD) of adiposity for each SNP.  
   
adiposity-
increasing /  
 Homozygous for  
Adiposity non-
increasing allele 
Heterozygous Homozygous for  
adiposity-increasing 
allele 
Gene rs number other allele  Mean SD Mean SD Mean SD 
NRXN3 rs10150332 C/T  99.7   9.69  100.0   9.81  101.1 10.49 
BDNF rs10767664 A/T  99.6   10.43 99.4   9.31  100.1 9.94 
GNPDA2 rs10938397 G/A  99.5   10.02 99.9   9.70  100.3 9.53 
LRRN6C rs10968576 G/A  99.9   9.89  99.8   9.67  99.8 9.66 
PRKD1 rs11847697 T/C  99.7   9.68  100.9  10.66 99.4 6.81 
GPRC5B rs12444979 C/T  98.6   8.71  99.9   9.65  99.9 9.84 
CADM2 rs13078807 G/A  99.6   9.61  100.3  10.01 99.6 10.27 
SLC39A8 rs13107325 T/C  99.8   9.73  100.2  10.10 100.2 7.61 
TNNI3K rs1514175 A/G  99.7   9.75  99.7   9.51  100.5 10.44 
PTBP2 rs1555543 C/A  99.5  9.67  100.0  9.89  99.7 9.65 
FTO rs1558902 A/T  98.9   9.28  100.1  10.00 101.0 9.95 
NUDT3 rs206936 G/A  100.0  9.77  99.4   9.70  100.0 10.31 
FLJ35779 rs2112347 T/G  99.3   9.82  99.9   9.75  99.9 9.78 
MAP2K5 rs2241423 G/A  99.6   9.89  99.9   10.00 99.8 9.63 
QPCTL rs2287019 C/T  99.3   8.72  100.0   9.89  99.8 9.77 
NEGR1 rs2815752 A/G  99.2   9.11  100.1  9.92  99.7 9.86 
TMEM18 rs2867125 C/T  98.0   9.12  99.3   9.43  100.1 9.92 
LRP1B rs2890652 C/T  99.7   9.64  100.1  10.02 99.8 10.54 
KCTD15 rs29941 G/A  98.9   9.73  99.8   9.67  100.1 9.86 
TMEM160 rs3810291 A/G  99.3   10.48 99.6   9.60  100.2 9.79 
MTCH2 rs3817334 T/C  99.7   9.64  99.5  9.63  101.0 10.38 
MTIF3 rs4771122 G/A  99.8   9.81  100.0  9.82  99.3 8.98 
ZNF608 rs4836133 A/C  100.2  10.01 99.7   9.64  99.8 9.78 
RPL27A rs4929949 C/T  99.6   9.52  100.0   9.88  99.8 9.76 
SEC16B rs543874 G/A  99.5   9.55  100.3  9.99  101.5 10.86 
MC4R rs571312 A/C  99.4   9.42  100.3  10.11 101.1 10.94 
RBJ rs713586 C/T  99.1   9.98  99.8   9.63  100.7 9.76 
FAIM2 rs7138803 A/G  99.6   9.67  99.9   9.87  100.6 9.72 
SH2B1 rs7359397 T/C  99.6   9.70  99.8   9.83  100.2 9.76 
FANCL rs887912 T/C  100.0   9.66  99.7   9.93  99.8 9.71 
ETV5 rs9816226 T/A  98.0   8.58  99.6   9.87  100.0 9.77 
TFAP2B rs987237 G/A  99.7   9.74  99.9   9.81  101.1 9.98 
 
 
 
Table 3. OLS and IV estimates of the average response in standardised KS3, systolic and diastolic blood pressure  
 
Dependent variable: 
 (1) 
KS3 
 (2)  
Systolic blood pressure 
 (3)  
Diastolic blood pressure 
 Coeff p-value Coeff p-value Coeff p-value 
Panel A: OLS       
   Fat mass coefficient and p-value -0.092 <0.001 0.227 <0.001 0.116 <0.001 
   95% confidence interval [-0.118, -0.065] [0.188, 0.266] [0.088, 0.144] 
    
Panel B: First stage IV     
   Unweighted allelic score 0.349 <0.001 0.365 <0.001 0.365 <0.001 
 [0.270, 0.428] [0.279, 0.451] [0.279, 0.451] 
Panel C: Second stage IV    
   Fat mass coefficient and p-value 0.114 0.301 0.373 0.006 0.205 0.041 
   95% confidence interval [-0.102, 0.331] [0.105, 0.642] [0.009, 0.402] 
First stage F-statistic 75.47 68.78 68.78 
IV: p-value, Hausman test 0.054 0.276 0.365 
Number of observations 4844 4047 4047 
Notes: Column 1, 2 and 3 show the results, where the outcome variable is KS3, systolic and diastolic blood pressure, respectively. 
All analyses control for ancestry-informative principal components. 95% confidence intervals in square brackets; p-value is the p-
value for standard t-ratio. 
36 
 
 
Table 4.  IV robustness analyses: different specifications of the instrument 
 
Dependent variable: 
 (1) 
KS3 
 (2)  
Systolic blood 
pressure 
 (3)  
Diastolic blood 
pressure 
 Coeff p-value Coeff p-value Coeff p-value 
Panel A: Mutually exclusive instruments    
   Coefficient and p-value 0.039 0.695 0.299 0.015 0.205 0.026 
   95% confidence interval [-0.16, 0.23] [0.06, 0.54] [0.03, 0.39] 
First stage F-statistic 8.90 8.20 8.20 
IV: p-value, Hausman test 0.183 0.962 0.482 
IV: p-value, Hansen J-test 0.862 0.574 0.531 
    
Panel B: 32 independent SNPs  
   Coefficient and p-value -0.035 0.643 0.354 <0.001 0.093 0.195 
   95% confidence interval [-0.18, 0.11] [0.16, 0.54] [-0.05, 0.23] 
First stage F-statistic 4.93 4.38 4.38 
IV: p-value, Hausman test 0.508 0.176 0.859 
IV: p-value, Hansen J-test 0.039 0.594 0.602 
    
Panel C: No. of adiposity-increasing alleles for each of the 32 SNPs  
   Coefficient and p-value -0.031 0.647 0.372 <0.001 0.168 0.011 
   95% confidence interval [-0.16, 0.10] [0.20, 0.55] [0.04, 0.30] 
First stage F-statistic 3.11 2.63 2.63 
IV: p-value, Hausman test 0.277 0.082 0.267 
IV: p-value, Hansen J-test 0.422 0.531 0.144 
    
Panel D: Weighted allelic score  
   Coefficient and p-value 0.080 0.370 0.452 <0.001 0.174 0.038 
   95% confidence interval [-0.10, 0.26] [0.23, 0.68] [0.01, 0.34] 
First stage F-statistic 116.7 101.3 101.3 
IV: p-value, Hausman test 0.049 0.045 0.482 
IV: p-value, Hansen J-test - - - 
    
Panel E: Selected instruments in weighted score   
   Coefficient and p-value 0.116 0.239 0.542 <0.001 0.182 0.037 
   95% confidence interval [-0.08, 0.31] [0.30, 0.78] [0.01, 0.35] 
First stage F-statistic 96.59 91.68 91.68 
IV: p-value, Hausman test 0.029 0.444 0.444 
IV: p-value, Hansen J-test - - - 
    
Panel F: Using only FTO and MC4R    
   Coefficient and p-value 0.139 0.312 0.666 <0.001 0.230 0.082 
   95% confidence interval [-0.13, 0.41] [0.30, 1.03] [-0.03, 0.49] 
First stage F-statistic 24.54 21.81 21.81 
IV: p-value, Hausman test 0.078 0.011 0.340 
IV: p-value, Hansen J-test 0.403 0.192 0.147 
    
Number of observations 4844 4047 4047 
Notes: See notes to Table 3. Panel A shows the IV estimate using the mutually exclusive instrumental variables, indicating the 
number of adiposity-increasing alleles carried by each child. Panel B uses the 32 independent SNPs as 32 instruments. Panel C 
specifies the number of adiposity-increasing alleles for each SNP as separate instruments (i.e. 64 instruments). Panel D uses a 
weighted allelic score, where the weights at each locus are defined by the effect size of the variant on adiposity, as estimated in an 
independent meta-analysis (Speliotes et al., 2010). All analyses control for ancestry-informative principal components. 95% 
confidence intervals in square brackets; p-value is p-value for standard t-ratio. 
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Table 5.  IV robustness analyses: LIML and Fuller(1)  
 
Dependent variable: 
 (1) 
KS3 
 (2)  
Systolic blood pressure 
 (3)  
Diastolic blood pressure 
 Coeff p-value Coeff p-value Coeff p-value 
Panel A: LIML    
   Fat mass coefficient and p-value -0.001 0.991 0.477 0.002 0.216 0.084 
   95% confidence interval [-0.196, 0.194] [0.179, 0.775] [-0.029, 0.462] 
First stage F-statistic 3.11 2.63 2.63 
p-value, Hausman test 0.277 0.082 0.267 
p-value, Hansen J-test 0.434 0.608 0.156 
    
Panel B: Fuller(1)    
   Coefficient and p-value -0.002 0.985 0.474 0.002 0.215 0.082 
   95% confidence interval [-0.195, 0.192] [0.180, 0.769] [-0.027, 0.458] 
First stage F-statistic 3.11 2.63 2.63 
p-value, Hausman test 0.277 0.082 0.267 
p-value, Hansen J-test 0.433 0.605 0.156 
    
Number of observations 4844 4047 4047 
Notes: The models include 64 instruments, indicating whether the child carries each of the adiposity-increasing alleles for each 
SNP (as in Panel C of Table 4). All analyses control for ancestry-informative principal components. See also notes to Table 3. 
 
 
 
 
 
 
 
Table 6.  IV robustness analyses: different specifications of the variable of interest 
 
Dependent variable: 
 (1) 
KS3 
 (2)  
Systolic blood pressure 
 (3)  
Diastolic blood pressure 
 Coeff p-value Coeff p-value Coeff p-value 
Panel A: Pr(Underweight)    
   Coefficient and p-value -5.861 0.315 -19.26 0.021 -10.56 0.065 
   95% confidence interval [-17.3, 5.6] [-35.66, -2.85] [-21.77, 0.64] 
First stage F-statistic 19.91 18.22 18.22 
p-value, Hausman test 0.205 0.012 0.060 
    
Panel B: Pr(Overweight)    
   Coefficient and p-value 3.916 0.310 13.31 0.009 7.117 0.044 
   95% confidence interval [-3.64, 11.47] [3.46, 22.49] [0.21, 14.03] 
First stage F-statistic 45.49 40.24 40.24 
p-value, Hausman test 0.106 0.139 0.242 
    
Number of observations 4844 4047 4047 
Notes: See notes to Table 3. Panel A presents the estimates for the effect of being underweight; Panel B shows the estimates for 
being overweight.  
 
 
 
 
 
 
 
 
  
38 
 
Table 7.  IV robustness analyses: subgroup analysis 
 
Dependent variable: 
 (1) 
KS3 
 (2)  
Systolic blood pressure 
 (3)  
Diastolic blood pressure 
 Coeff p-value Coeff p-value Coeff p-value 
Panel A: Girls    
   Coefficient and p-value 0.243 0.106 0.426 0.035 0.447 0.004 
   95% confidence interval [-0.05, 0.54] [0.03, 0.82] [0.14, 0.75] 
First stage F-statistic 43.43 33.65 33.65 
p-value, Hausman test 0.008 0.263 0.020 
Number of observations 2469 2089 2089 
    
Panel B: Boys    
   Coefficient and p-value -0.029 0.866 0.329 0.088 -0.043 0.767 
   95% confidence interval [-0.37, 0.31] [-0.05, 0.71] [-0.33, 0.24] 
First stage F-statistic 32.62 34.51 34.51 
p-value, Hausman test 0.736 0.738 0.228 
Number of observations 2375 1958 1958 
    
Notes: See notes to Table 3. Panels A and B present the estimates for girls and boys respectively.  
 
 
 
 
 
Table 8.  IV robustness analyses: controlling for covariates 
  (1) 
KS3 
 (2)  
Systolic blood pressure 
 (3)  
Diastolic blood pressure 
 Coeff p-value Coeff p-value Coeff p-value 
Panel A: Covariates: gender    
   Fat mass coefficient and p-value 0.111 0.319 0.379 0.006 0.206 0.042 
   95% confidence interval [-0.11, 0.33] [0.11, 0.65] [0.01, 0.40] 
First stage F-statistic 77.18 69.51 69.51 
p-value, Hausman test 0.044 0.288 0.371 
    
Panel B: Covariates: gender, maternal education, social class at birth, IMD  
   Fat mass coefficient and p-value 0.092 0.342 0.379 0.007 0.206 0.046 
   95% confidence interval [-0.10, 0.28] [0.10, 0.66] [0.00, 0.41] 
First stage F-statistic 79.61 68.61 68.61 
p-value, Hausman test 0.122 0.288 0.363 
    
Panel C: Covariates: all1    
   Fat mass coefficient and p-value 0.090 0.322 0.374 0.008 0.201 0.052 
   95% confidence interval [-0.09, 0.27] [0.10, 0.65] [-0.00, 0.40] 
First stage F-statistic 81.56 69.35 69.35 
p-value, Hausman test 0.156 0.284 0.382 
    
N 4844 4047 4047 
Notes: See notes to Table 3. All analyses control for ancestry-informative principal components. 1 All covariates includes: child 
birth weight, age at KS3 (in months), ln(income), mother’s educational attainment, a binary indicator whether the child was raised 
by the natural father, social class at birth, dummy variables indicating whether the mother works part-time or full-time, and whether 
the partner is employed, the Index of Multiple Deprivation (IMD, measured at birth), binary variables indicating whether the 
mother drank alcohol during pregnancy, and whether the mother smoked during pregnancy, the duration of breastfeeding, and 
mother’s age at birth. The definition of the covariates is given in the note to Table B1, Appendix B.  
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Web Appendix: Supplemental Information 
1. Maternal behaviours, characteristics, and genotypes 
Table S1 below indirectly examines whether mothers’ behaviours or characteristics are related to their 
genotype. It presents the coefficients (standard errors) of a regression of the covariate (i.e. the maternal 
behaviour / characteristic) in the first column on the unweighted maternal allelic score (columns 1 and 2) or 
weighted maternal allelic score (columns 3 and 4). The final column shows the p-value of an F-statistic 
testing whether the coefficients on the 32 independent maternal variants jointly equal zero.  
With random assignment of the genetic variants, there should be no systematic variation in the 
characteristics and behaviours by genotype. We find some significant differences. For example, more risk 
alleles are associated with a higher probability that the mother is employed part-time. However, there is 
little evidence of any systematic differences for the different covariates shown here. 
 
Table S1: An indirect test of independence: regressing the covariate on the maternal genetic variants 
 Unweighted allelic score 
 
Weighted allelic score 32 independent variants 
 Coefficient Standard 
error 
Coefficient Standard 
error 
p-value of F-test: 
instrument-coefficients 
jointly equal to zero 
Mother’s education -0.00 (0.00) -0.02 (0.02) 0.172 
Mother’s age at birth -0.00 (0.00) -0.04 (0.03) 0.076 
Raised by natural father -0.00 (0.00) -0.00 (0.01) 0.275 
Mum works part-time 0.00** (0.00) 0.02* (0.01) 0.097 
Mum works full-time 0.00 (0.00) 0.00 (0.01) 0.371 
Alcohol during pregnancy 0.00 (0.00) 0.03* (0.01) 0.402 
Smoke during pregnancy  0.00 (0.00) 0.01 (0.01) 0.270 
Breastfeeding -0.00 (0.01) 0.01 (0.03) 0.040 
Mother’s locus of control 0.02 (0.04) 0.31 (0.27) 0.319 
Mother’s teaching score 0.00 (0.00) 0.02 (0.03) 0.139 
Mother’s engagement with 
child’s activities 
0.00 (0.00) 0.00 (0.01) 0.258 
Parental engagement in active 
play with child 
0.00 (0.02) 0.04 (0.13) 0.098 
Notes: * p<0.1; ** p<0.05; *** p<0.01; The p-value in the last column corresponds to an F-test of the coefficients on the 32 
maternal instrumental variables jointly equalling zero. Mother’s educational level is a categorical variable with four values (less than 
ordinary O-level, O-level, A-level, and university degree). Breastfeeding is a categorical variable (never, <1 month, 1-3 months and 
3+ months). Locus of control is a psychological concept that describes whether individuals attribute successes and failures to 
internal or external causes. Those with an internal (low) locus of control see themselves as responsible for the outcomes of their 
actions; those with an external (high) locus of control believe that successes and failures are chance-determined. Mother’s teaching 
score is constructed from questions that measure whether the mother is involved in teaching her child (depending on the child’s 
age) songs, the alphabet, being polite, etc. We use an average score from three measures at ages 18, 30 and 42 months to capture 
longer-term involvement. The mother’s engagement with the child’s activities measures the extent to which the mother reads/sings 
to the child, helps the child build towers, etc. Parental engagement with active play is a continuous indicator measuring the extent 
to which the parents engage in active (outdoor) activities with their children, such as going to the park, going swimming, etc. The 
sample contains 4,925 observations. 
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2. The 32 Genetic Variants 
Table S2 shows the 32 genetic variants used in our analysis, and briefly lists what the variant has been shown 
to be associated with. The majority of the information below is obtained from the GWAS catalogue10, and 
www.SNPedia.com. However, we note that the genetic variants are very likely to be associated with 
additional phenotypes not listed here, either because studies that have explored these associations were 
underpowered, or because studies have not (yet) investigated that specific relationship.  
Wherever possible, we also discuss what is known about the variant’s mechanism. However, as very little 
is known about the function of specific genes, this information is limited. For example, even for the FTO 
genetic variant, the one that accounts for the largest proportion of the variation in fat mass (and with that, 
the one studied most extensively, as it is the easiest to identify), the physiological function is unknown, with 
the current evidence only suggesting that it affects obesity through increased consumption of fat and energy, 
and diminished satiety. As there are – in some cases – hundreds of studies showing the association between 
the genetic variant and body mass index or obesity (for the largest GWAS, see Speliotes et al., (2010)), Table 
S2 only cites studies that find associations with outcomes other than adiposity-related phenotypes.  
 
Table S2: Known functions of the 32 genetic variants used in our analyses 
rs number Gene Associations: 
rs10150332 NRXN3 Shown to be associated with body mass index, obesity, and fat distribution 
(waist to hip ratio). One study finds an association between NRXN3 and 
schizophrenia (Wang et al., 2014).  
rs10767664 BDNF BDNF codes for proteins that are responsible for maintaining energy balance 
through food consumption and energy expenditure (Garver et al., 2013). 
rs10767664 has also been associated with allergic asthma (Andiappan et al, 2011) 
and allergic rhinitis (Jin et al., 2015). Furthermore, the BDNF gene has been 
implicated in learning and memory among rodents (Cunha et al., 2010) 
rs10938397 GNPDA2 Shown to be related to body mass index, fat mass percentage, waist circumference, 
waist-to-height ratio, obesity and other health states associated with obesity, such 
as type II diabetes and cardiovascular risk (He et al., 2010; Xi et al., 2013)  
rs10968576 LRRN6C Shown to be associated with body mass index and obesity 
rs11847697 PRKD1 Shown to be associated with body mass index and obesity 
rs12444979 GPRC5B Shown to be associated with body mass index and obesity 
rs13078807 CADM2 Shown to be associated with body mass index and obesity. One study also shows 
an association between rs13078807 and hyperactivity/impulsivity, but could not 
replicate this in an independent sample (Albayrak et al., 2013) 
rs13107325 SLC39A8 Shown to be associated with body mass index, obesity. It is also related to blood 
pressure and HDL cholesterol, outcomes associated with obesity, and likely on 
the causal pathway. This SNP has also been associated with schizophrenia 
(Carrera et al., 2012) 
rs1514175 TNNI3K Shown to be associated with body mass index and obesity 
rs1555543 PTBP2 Shown to be associated with body mass index and obesity 
rs1558902 FTO Shown to be associated with body mass index, obesity, waist circumference, 
weight, and metabolic syndrome. It is also related to other outcomes associated 
with obesity, such as type II diabetes, and age at menarche, and asthma. It is 
expressed in the hypothalamus and functionally involved in energy homeostasis. 
The SNP is believed to affect obesity through an increased consumption of fat 
and energy (Timpson et al., 2008, Cecil et al., 2008, Richmond and Timpson, 
2012), as well as due to diminished satiety (Wardle et al., 2008) 
                                                 
10 Available at: https://www.genome.gov/page.cfm?pageid=26525384&clearquery=1#searchForm 
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rs206936 NUDT3 Shown to be associated with body mass index and obesity. One study also shows 
an association between rs206936 and inattention, but could not replicate this in 
their meta-analysis (Albayrak et al., 2013) 
rs2112347 FLJ35779 Shown to be associated with body mass index and obesity 
rs2241423 MAP2K5 Shown to be associated with body mass index and obesity. One study shows an 
association between rs2241423 and hyperactivity, but could not replicate this in 
their meta-analysis (Albayrak et al., 2013) 
rs2287019 QPCTL Shown to be associated with body mass index, obesity and the insulinogentic 
index (for the latter, see Burgdorf et al., 2012) 
rs2815752 NEGR1 Shown to be associated with body mass index and obesity. One study also shows 
an association between rs2815752 and white matter integrity (Dennis et al., 2014) 
rs2867125 TMEM18 Shown to be associated with body mass index and obesity 
rs2890652 LRP1B Shown to be associated with body mass index, obesity and insulin resistance (for 
the latter, see Burgdorf et al., 2012) 
rs29941 KCTD15 Shown to be associated with body mass index, obesity, metabolic syndrome, and 
colorectal cancer risk, though the association with colorectal cancer risk turned 
insignificant after adjustment for multiple comparisons (for the latter, see Lim et 
al., 2012) 
rs3810291 TMEM160 Shown to be associated with body mass index and obesity 
rs3817334 MTCH2 Shown to be associated with body mass index and obesity 
rs4771122 MTIF3 Shown to be associated with body mass index and obesity 
rs4836133 ZNF608 Shown to be associated with body mass index and obesity. One study also shows 
an association with Alzheimer’s disease risk (for the latter, see Hinney et al., 2014) 
rs4929949 RPL27A Shown to be associated with body mass index and obesity 
rs543874 SEC16B Shown to be associated with body mass index and obesity. It is also related to 
the age at menarche, an outcome associated with obesity 
rs571312 MC4R Shown to be associated with body mass index, obesity, and colorectal cancer risk, 
though the association with colorectal cancer risk turned insignificant after 
adjustment for multiple comparisons (for the latter, see Lim et al., 2012). MC4R 
codes for proteins that are responsible for maintaining energy balance through 
food consumption and energy expenditure (Garver et al., 2013). Like FTO, it is 
associated with an increased consumption of fat and energy and decreased energy 
expenditure 
rs713586 RBJ Shown to be associated with body mass index and obesity. One study also shows 
an association with Alzheimer’s disease risk (for the latter, see Hinney et al., 2014) 
rs7138803 FAIM2 Shown to be associated with body mass index, obesity, fat mas percentage, waist 
circumference, weight, metabolic syndrome, and waist-to-height ratio 
rs7359397 SH2B1 Shown to be associated with body mass index and obesity, total fat, waist 
circumference, serum leptin (Jamshidi et al., 2007), and insulin sensitivity (Fall et 
al., 2012) 
rs887912 FANCL Shown to be associated with body mass index and obesity 
rs9816226 ETV5 Shown to be associated with body mass index and obesity 
rs987237 TFAP2B Shown to be associated with body mass index, obesity, and adiposity 
 
 
  
42 
 
3. Gene-environment interactions 
Monotonicity can be violated by gene-environment interactions. We explore the existence of such 
interactions indirectly, by testing whether the association between fat mass and the allelic score differs in 
different ‘environments’. Although one can never observe all potentially relevant environments, we explore 
the importance of a set of environments that have been shown to be important for child development. In 
particular, we investigate whether the effect of the allelic score differs by (1) the child’s gender, (2) birth 
weight, (3) breastfeeding duration, (4) social class at the child’s birth, (5) maternal education, (6) family 
income, and (7) deprivation. Specifically, we interact the allelic score with each of these environments in a 
regression of fat mass on the interactions (i.e. the first stage). We then test whether the interaction-
coefficients can be statistically distinguished in different environments.  
Table S3 presents the results. This shows that the effect of the allelic score on adiposity differs slightly in 
different environments. For example, one additional risk allele increases adiposity in boys by 0.33 (about 
3% of a standard deviation), and in girls with 0.36. However, we cannot statistically distinguish between 
these estimates (p = 0.70). Similarly, there is little evidence of gene-environment interactions in the analyses 
presented in columns 2 to 7.  
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Table S3. Gene-environment interactions 
 (1) 
Gender 
(2) 
Birth weight 
(3) 
Duration of 
breastfeeding 
(4) 
Social class at 
birth 
(5) 
Maternal 
education 
(6) 
Family 
income 
(7) 
Index of 
Multiple 
Deprivation 
        
Allelic score, group 1 0.36*** 0.36*** 0.37*** 0.38*** 0.37*** 0.28*** 0.27*** 
 (0.06) (0.08) (0.10) (0.06) (0.11) (0.08) (0.08) 
Allelic score, group 2 0.33*** 0.38*** 0.25*** 0.31*** 0.39*** 0.42*** 0.38*** 
 (0.06) (0.08) (0.10) (0.06) (0.06) (0.08) (0.08) 
Allelic score, group 3  0.36*** 0.37*** 0.40*** 0.34*** 0.42*** 0.35*** 
  (0.08) (0.10) (0.13) (0.08) (0.08) (0.08) 
Allelic score, group 4  0.30*** 0.37***  0.21*** 0.28*** 0.44*** 
  (0.08) (0.06)  (0.10) (0.08) (0.08) 
        
p-value testing equality of G*E 0.70 0.91 0.74 0.68 0.48 0.40 0.56 
Number of observations 4844 4844 4844 4844 4844 4844 4844 
Notes: The estimates in each column are obtained from one regression. This is a regression of fat mass on the allelic score, the ‘environment’ indicated in the column heading (e.g. gender, birth weight), 
and their interaction, as well as the 10 ancestry-informative principal components. For column 1, group 1 and 2 indicate girls and boys respectively. In column 2, groups 1 to 4 indicate the quartiles of 
the birth weight distribution. The duration of breastfeeding is grouped as no breastfeeding (group 1), less than 1 month (group 2), between 1-3 months (group 3), and 4 or more months (group 4). Social 
class at birth (column 4) is subdivided into professional/managerial/technical (group 1), non-manual and manual skilled (group 2), and semi-skilled/unskilled (group 3). Column 5, maternal education, 
indicates less than O-level (group1), O-level (group 2), A-level (group 3), and university degree (group 4). In columns 6 and 7, groups 1 to 4 indicate the quartiles of the income and IMD distribution 
respectively. The “p-value testing equality of G*E” is the p-value of an F-test testing whether the coefficient on the different groups are significantly different from each other.  
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